<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.976887,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpWBxAFD1wVBUNQTV4ER0sPBAJaAA1eVhdTF0EPAQ0DQExOH1VbRAgbVFJTVB1aVAAACQFKUxMODQ==","queueTime":0,"ttGuid":"c0a95436f1d437c3"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full">
<meta property="description" name="description" content="Background: Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited liter...">
<meta property="og:title" name="title" content="Frontiers | Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China">
<meta property="og:description" name="description" content="Background: Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited liter...">
<meta name="keywords" content="hereditary,transthyretin amyloidosis,cardiomyopathy,prognosis,China">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="9">
<meta name="citation_journal_title" content="Frontiers in Cardiovascular Medicine">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Cardiovasc. Med.">
<meta name="citation_issn" content="2297-055X">
<meta name="citation_doi" content="10.3389/fcvm.2022.900313">
<meta name="citation_firstpage" content="900313">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China">
<meta name="citation_keywords" content="hereditary; transthyretin amyloidosis; cardiomyopathy; prognosis; China">
<meta name="citation_abstract" content="Background: Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited literature describing the variants responsible for ATTRv in areas outside the United State, the United Kingdom and Europe. This study was performed to describe the clinical characteristics and genotypic profiles of this disease in South China. Methods: This was a single-center retrospective study that evaluated 29 patients with a confirmed diagnosis of hereditary transthyretin amyloid cardiomyopathy enrolled from January 2016 to November 2021. Results: 93.1% patients were male and the median age of symptom onset was 53 (46, 62.5) years old. The initial manifestations of ATTR-CM were cardiovascular symptoms (55.2%), neuropathy (41.4%) and vitreous opacity (3.4%). Phenotypes at diagnosis were mixed (82.8%), predominant cardiac (6.9%), neurological (6.9%) and ophthalmic (3.4%). Poor R-wave progression (41%), pseudo-infarct (31%) and low-voltage (31%) patterns were common findings on electrocardiogram. Unexplained increased wall thickness was observed in all 29 patients, with mean septal and posterior wall thicknesses of 14.256.26 mm and 15.342.84 mm, respectively. Diastolic dysfunction was also seen in all 29 patients, and 17 (58%) had a restrictive fill pattern at diagnosis. Nine different missense mutations of the TTR gene were found in 29 patients from 23 families, with c.349GT (p.Ala117Ser) the most common mutation. The median survival time after diagnosis was 47.6 (95% CI 37.9-57.4) months, with 1, 3 and 5-year survival rates of 91.2%, 74% and 38% respectively. Patients with advanced heart failure (National Amyloidosis Staging stage II/III) had worse survival than stage I [Breslow (Generalized Wilcoxon), 2=4.693, P=0.03)]. Conclusions: ATTR amyloidosis genotypes and phenotypes are highly heterogeneous. Advanced heart failure predicts a poor prognosis. Understanding the  different clinical profiles of ATTR cardiac amyloidosis with different genotype is important to its early recognition.  ">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2022/06/07">
<meta name="citation_publication_date" content="2022/06/27">
<meta name="citation_author" content="Wang, Shuai ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Peng, Wenke ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Pang, Min ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Mao, Ling ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Peng, Daoquan ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Yu, Bilian ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Wu, Sha ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Hu, Die ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Yang, Yang ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="He, Jia ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="citation_author" content="Ouyang, Mingqi ">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China">
<meta name="dc.identifier" content="doi:10.3389/fcvm.2022.900313">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China","author":[{"@type":"Person","name":"Shuai Wang","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Wenke Peng","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Min Pang","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Ling Mao","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Daoquan Peng","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Bilian Yu","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Sha Wu","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Die Hu","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Yang Yang","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Jia He","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]},{"@type":"Person","name":"Mingqi Ouyang","affiliation":["Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China"]}],"datePublished":"2022-06-27","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2022","isPartOf":{"@type":"PublicationVolume","volumeNumber":"9","isPartOf":{"@type":"Periodical","name":"Frontiers in Cardiovascular Medicine"}}},"citation":["https://doi.org/10.3389/fcvm.2022.900313"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="red"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/cardiovascular-medicine" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Cardiovasc. Med.</span><span>, 27 June 2022</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Heart Failure and Transplantation</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 9 - 2022 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fcvm.2022.900313">https://doi.org/10.3389/fcvm.2022.900313</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Novel Phenotyping and Risk Stratification Strategies for Heart Failure</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 16 articles" href="https://www.frontiersin.org/research-topics/26330/novel-phenotyping-and-risk-stratification-strategies-for-heart-failure/magazine" target="_self" data-event="customLink-linkType-a_viewAll16Articles"><span>View all 16 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>

<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/1615373" class="user-id-1615373"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1615373/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Shuai Wang">Shuai Wang</a></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Wenke Peng" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Wenke Peng</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Min Pang" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Min Pang</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ling Mao" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ling Mao</span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1406875" class="user-id-1406875"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1406875/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Daoquan Peng&#xA;">Daoquan Peng</a><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Bilian Yu" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Bilian Yu</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sha Wu" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sha Wu</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Die Hu" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Die Hu</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Yang Yang" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Yang Yang</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jia He" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jia He</span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Mingqi Ouyang" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Mingqi Ouyang</span></div>
<ul class="notes"><li class="pl0">Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, China</li>
</ul>
<p class="mb15"><strong>Background:</strong> Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited literature describing the variants responsible for ATTRv in areas outside the United State, the United Kingdom and Europe. This study was performed to describe the clinical characteristics and genotypic profiles of this disease in South China.</p>
<p class="mb15"><strong>Methods:</strong> This was a single-center retrospective study that evaluated 29 patients with a confirmed diagnosis of hereditary transthyretin amyloid cardiomyopathy enrolled from January 2016 to November 2021.</p>
<p class="mb15"><strong>Results:</strong> 93.1% patients were male and the median age of symptom onset was 53 (46, 62.5) years old. The initial manifestations of ATTR-CM were cardiovascular symptoms (55.2%), neuropathy (41.4%) and vitreous opacity (3.4%). Phenotypes at diagnosis were mixed (82.8%), predominant cardiac (6.9%), neurological (6.9%) and ophthalmic (3.4%). Poor R-wave progression (41%), pseudo-infarct (31%) and low-voltage (31%) patterns were common findings on electrocardiogram. Unexplained increased wall thickness was observed in all 29 patients, with mean septal and posterior wall thicknesses of 14.25 &#x000B1; 6.26 mm and 15.34 &#x000B1; 2.84 mm, respectively. Diastolic dysfunction was also seen in all 29 patients, and 17 (58%) had a restrictive fill pattern at diagnosis. Nine different missense mutations of the TTR gene were found in 29 patients from 23 families, with c.349G&#x0003E;T (p.Ala117Ser) the most common mutation. The median survival time after diagnosis was 47.6 (95% CI 37.9-57.4) months, with 1, 3 and 5-year survival rates of 91.2%, 74% and 38% respectively. Patients with advanced heart failure (National Amyloidosis Staging stage II/III) had worse survival than stage I [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, <i>P</i> = 0.03)].</p>
<p class="mb0"><strong>Conclusions:</strong> ATTR amyloidosis genotypes and phenotypes are highly heterogeneous. Advanced heart failure predicts a poor prognosis. Understanding the different clinical profiles of ATTR cardiac amyloidosis with different genotype is important to its early recognition.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a>
<h2>Introduction</h2>
<p class="mb15">Hereditary transthyretin amyloidosis (ATTRv) represents a group of severe diseases with a broad spectrum of genotypes and phenotypes caused by transthyretin (TTR) gene mutations. ATTR is the result of dissociation of the transthyretin tetramer into monomers that mis-fold, forming amyloid deposits in the extracellular space (<a href="#B1">1</a>). The most common manifestations of ATTR are polyneuropathy and cardiomyopathy (<a href="#B2">2</a>). As our understanding of the molecular mechanisms behind ATTR amyloidosis improves, disease-modifying treatments including stabilizing molecular (tafamidis) and genetic silencers (partisiran and inotersen) have been made available. As pharmacotherapy is more effective in the early stages of the disease, the early diagnosis of ATTR by understanding its genotype-phenotype correlations is important (<a href="#B3">3</a>&#x02013;<a href="#B5">5</a>).</p>
<p class="mb0">More than 120 mutations of the TTR gene have been described, and as of December 2021 there are 68 pathogenic/likely pathogenic variants of the TTR gene listed in the National Center for Biotechnology Information ClinVar database (<a href="#B6">6</a>&#x02013;<a href="#B8">8</a>). Some genotype-phenotype variability has been reported. Although the THAOS registry collected ATTR phenotypes and genotypes from continental Western Europe and the United States, few studies have been performed in China. Two recent retrospective cohort studies revealed that the mutation of TTR in Chinese patients may be quite different from that seen in the United States and Europe (<a href="#B9">9</a>, <a href="#B10">10</a>). Further, those two studies mainly discussed ATTRv patients from northern China and one study focused on ATTRv patients with neuropathy as main symptom. Here, we report the phenotype and genotype of 29 patients with ATTRv cardiomyopathy (ATTRv-CM) from 23 unrelated South Chinese families.</p>
<a id="h3" name="h3"></a>
<h2>Methods</h2>
<h3 class="pt0">Study Design and Population</h3>
<p class="mb0">This was a descriptive, observational, and retrospective study that included patients diagnosed with hereditary ATTRv-CM at our institution from January 2016 to November 2021. The study was undertaken in accordance with the Declaration of Helsinki and was approved by the ethics committee of Second Xiangya Hospital. Due to the retrospective nature of this study, informed consent was waived for patients who had died. Otherwise, all patients provided written informed consent.</p>
<h3>Diagnosis of Hereditary ATTR Cardiac Amyloidosis</h3>
<p class="mb15">The diagnosis of hereditary ATTRv-CM was established by clinical presentation, family history, echocardiography, tissue biopsy and DNA sequencing for the presence of a mutation in the TTR gene. Cardiac magnetic resonance (CMR) and <sup>99m</sup>technetium (<sup>99m</sup>Tc)-pyrophosphate (PYP) scintigraphy were performed in select cases. All included patients had a positive tissue biopsy (endocardium or extracardiac, e.g., abdominal adipose tissue or vitreous body) for amyloidosis and a pathogenic/likely pathogenic TTR variant. Light chain amyloidosis was ruled out by confirming a normal free light chain ratio and the absence of detectable serum and/or urine monoclonal protein. Patients without a related gene mutation on TTR gene sequencing were excluded.</p>
<p class="mb15">The date of symptom onset was reported by the patient as the date on which symptoms related to amyloidosis first were noted. The date of diagnosis was the date on which the diagnosis of amyloidosis was confirmed histologically.</p>
<p class="mb15">Phenotype categories based on clinical presentation at the time of diagnosis were: 1) predominantly cardiac. 2) predominantly neurological. 3) mixed (cardiac and neurological); and 4) ophthalmic. Patients with a predominantly cardiac phenotype were those (1) with heart failure, dyspnea and/or abnormal electrocardiogram findings caused by rhythm disturbance and (2) who did not have more than mild neurological or gastrointestinal symptoms (excluding erectile dysfunction, constipation and carpal tunnel syndrome). Patients with a predominantly neurologic phenotype were those with (1) walking disability of any severity, other neurologic symptoms of any severity or gastrointestinal symptoms (early satiety, nausea, vomiting, unintentional weight loss, diarrhea, constipation or fecal incontinence) of any severity and (2) who did not have heart failure, dyspnea, or an abnormal ECG due to a rhythm disturbance. Patients with a (3) mixed phenotype were patients who had at least 1 cardiac and neurological symptom as described above. Patients with (4) an ophthalmic phenotype had vitreous opacity with none of the cardiac or neurological symptoms described above.</p>
<p class="mb15">Cardiomyopathy was defined as an end-diastolic thickness of the left ventricular wall &#x0003E; 1.2 cm (in the absence of any other plausible causes of LV hypertrophy). Other clues suggestive of cardiac amyloidosis included granular sparkling appearance of the ventricular myocardium, increased thickness of the atrioventricular valves or the interatrial septum and reduced tissue doppler e&#x00027; velocities. CMR and <sup>99m</sup>Tc-PYP were performed in select cases. Characteristic CMR findings of (1) the inability to suppress or &#x0201C;null&#x0201D; the myocardial signal or (2) the presence of diffuse subendocardial or transmural enhancement patterns on late gadolinium enhancement CMR were recorded. Grade 2 or 3 cardiac uptake on <sup>99m</sup>Tc-PYP scintigraphy was also recorded.</p>
<p class="mb0">N-terminal pro-B type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), cardiac troponin (cTnT), modified poly neuropathy disability (PND) score and the U.K. National Amyloidosis Staging (NAC) and New York Heart Association (NYHA) stages were recorded. NAC Stage I is defined as NT-proBNP &#x02264; 3000 ng/L and eGFR &#x02265; 45 mL/min, and NAC stage III was defined as NT-proBNP&#x0003E; 3000 ng/L and eGFR &#x0003C; 45 mL/min. The remainder of the patients were assigned to NAC stage II.</p>
<h3>Neurological Work-Up</h3>
<p class="mb0">Neurological examination included an assessment of motor, cerebellar and reflex function as well as screening for sensory function. Muscle strength was documented according to the Medical Research Council (MRC) scale (5/5 normal strength, 0/5 no contractions). Motor and sensory nerve conduction studies were performed on patients with reported neurologic symptoms. The PND score was used to stage patients with ATTRv and polyneuropathy at baseline. PND I was defined as sensory disturbances in the extremities but preserved walking capacity; PND II was defined as difficulty walking but without the need for a walking stick; PND III was defined as sticks or crutches required for walking; and PND IV was defined as confined to a wheelchair or bed.</p>
<h3>Genetic Testing of the TTR Gene</h3>
<p class="mb0">Genomic DNA was isolated from whole peripheral blood using standard techniques. Exon 1&#x02013;4 of the <i>TTR</i> gene were amplified with polymerase chain reaction. Sequences of the <i>TTR</i> gene (NM_000371.3; NG_009490.1) were analyzed using the Applied BioSystems SeqScape software v4.0 (Carlsbad, USA) and the DNA Dynamo Sequence Analysis Software (North Wales, UK). The datasets presented in this study can be found in an online repository. The name of the repository and its accession numbers can be found in the supplementary material (<a href="#SM1">Supplementary Table 1</a>). Genetic testing and clinical penetrance assessments were performed on family members for probands if available.</p>
<h3>Follow-Up</h3>
<p class="mb0">Patient follow-ups at 6 to 12-month intervals included an ECG, NT-proBNP and yearly echocardiogram. Mutation carriers were surveilled via regular (yearly) telephone contact.</p>
<h3>Statistical Analyses</h3>
<p class="mb0">Continuous variables are reported as mean &#x000B1; SD or median and interquartile range (IQR) (for non-normal distributions). Categorical variables are reported as percentages. Kaplan-Meier survival was calculated from the date of the original diagnosis to the date of death or the most recent contact. Gehan-Breslow-Wilcoxon method was used to compare survival curves. All tests were 2-tailed and a <i>P</i>-value &#x0003C; 0.05 was considered statistically significant. Statistical analyses were performed using SPSS Statistics (version 26. IBM Corp., Chicago, IL, USA).</p>
<a id="h4" name="h4"></a>
<h2>Results</h2>
<h3 class="pt0">Clinical Characteristics of Patients With ATTR Cardiac Amyloidosis</h3>
<p class="mb0">The clinical characteristics at diagnosis of the 29 patients are summarized in <a href="#T1">Tables 1</a>, <a href="#T2">2</a>. Twenty-seven (93.1%) patients were male. The median age at symptom onset was 53 (46, 62.5) years and the median age at diagnosis was 56 (47.75&#x02013;66.25) years. The median time from symptom onset to diagnosis was 24 (12&#x02212;24) months and the median course from diagnosis to the last visit was 15 (6.5&#x02013;37.5) months.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" name="Table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>

</a>
<p><strong>Table 1</strong>. Clinical Manifestations of ATTRv-CM and the <i>TTR</i> variant Ala97Ser.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" name="Table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>

</a>
<p><strong>Table 2</strong>. Complementary baseline tests for ATTRv&#x02013;CM and the <i>TTR</i> variant Aal97Ser.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Dyspnea on exertion and limited physical capacity were the initial complaints that prompted a comprehensive cardiological examination in 16 cases (55.2%). Another 12 (41.4%) patients presented with distal sensory disturbances and/or weakness predominantly of the lower limbs. One patient reported vitreous opacity as their initial manifestation and had asymptomatic cardiac hypertrophy at diagnosis.</p>
<p class="mb15">Twenty-four (82.8%) patients presented with a mixed phenotype that included both cardiomyopathy and neuropathy, while 2 (6.9%) had a predominantly cardiac phenotype and 2 (6.9%) had a predominantly neurological phenotype. One patient (3.4%) presented with vitreous opacity with asymptomatic myocardial hypertrophy. Peripheral and autonomic nerve dysfunction were found in 25 (86.2%) and 14 (48.3%) subjects at diagnosis, respectively. Six patients (20.7%) had a history of uni- or bilateral carpal tunnel syndrome. Lumber spinal stenosis was reported in one patient. The PND score was used to describe the severity of the peripheral neuropathy (<a href="#T1">Table 1</a>). At diagnosis, 72.4% (21) had severe heart failure (NYHA III/IV), 3.4% (1) had mild heart failure (NYHA II) and 24.1% (7) had asymptomatic myocardial hypertrophy (<a href="#T1">Table 1</a>). Elevated NT-proBNP and cTnT were found in 29 (100%) and 28 (97%) patients, respectively. The median NT-proBNP and cTnT levels were 2789 (1206&#x02013;5024) pg/ml and 61.5 (42.8&#x02013;88.9) pg/ml at diagnosis. Only one patient had an eGFR &#x0003C;45 and the median eGFR was 81.7 (66.4&#x02013;93.6) ml/min/1.73 m<sup>2</sup> (<a href="#T2">Table 2</a>). Of the 29 patients, 19 (65.6%) were NAC stage I, 9 (31%) stage II and 1 (3.4%) stage III.</p>
<p class="mb15">Electrocardiogram abnormalities were evident in 15 (51.7%) patients at diagnosis. Two (6.9%) had atrial fibrillation, 5 (17.2%) presented with an atrial-ventricular block and 2 went on to require a permanent pacemaker. The classic low-voltage pattern of ATTR-CM was found in 9 (31%) patients, while a low-voltage pattern according to the Sokolow criteria was found in 8 (27.5%). A pseudo-infarct pattern was found in 9 (31%) patients and poor R wave progression was found in 12 (41%, <a href="#T2">Table 2</a>).</p>
<p class="mb0">Unexplained increased wall thickness (&#x0003E;12 mm) and diastolic dysfunction were observed in 29 (100%) patients. Two (6.9%) had systolic dysfunction with an ejection fraction &#x0003C;50%. Restrictive filling (e&#x00027; &#x0003C;5 cm/s) was present in 17 (58%) patients at diagnosis. Pericardial effusions were present in 9 patients (31%). The mean septal and posterior wall thicknesses of the cohort were 16.39&#x000B1;3.04 mm and 15.34&#x000B1;2.84 mm, respectively, and the mean systolic left atrial diameter was 39.47&#x000B1;5.54 mm. The mean LVEF was 52.65&#x000B1;10.6%. CMR was performed on 16 (55.2%) patients to diagnose ATTR cardiac amyloidosis, all of which showed diffuse subendocardial or transmural LGE and abnormal gadolinium kinetics. <sup>99m</sup>TC-PYP scintigraphy was performed on 9 patients (31%). Seven had grade 3 cardiac uptake and 2 patients had grade 2 uptake. Biopsies were performed on all patients, and originated from the abdominal fat (28), endomyocardium (1) or vitreous body (1) (<a href="#T2">Table 2</a>). All samples were positive on Congo red staining and TTR immunochemistry. Four patients (9.5%) in this cohort were on tafamidis post-enrollment, and no patient received a liver transplant.</p>
<h3>Genetic Spectrum of TTR Mutations</h3>
<p class="mb0">Genetic testing of the probands and their family members identified 9 different missense <i>TTR</i> mutations [Asp18Asn(p.Asp38Asn), Ser23Asn(p.Ser43Asn), Glu42Gly (p.Glu62Gly), Gly47Glu(p.Gly67Glu), Leu55Arg(p.Leu75Arg), Thr59Lys(p.Thr79Lys), Glu61Lys(p.Glu81Lys), His108Arg (p.His108Arg), Ala97Ser(p.Ala117Ser)] and 1 small deletion mutation (3&#x00027;UTR c.624_632 del GACTTCTCC) in 29 patients from 23 families. Pedigree analysis found another 11 asymptomatic mutation carriers without electrocardiographic and echocardiographic abnormalities. The predominant genotypes identified in ATTR-CA were the Ala97Ser (p.Ala117Ser) mutation (11/29, 37.9%) followed by Thr59Lys (p.Thr79Lys) (5, 17.2%) (<a href="#F1">Figure 1</a>). Of these variants, Asp18Asn, Ser23Asn, Glu42Gly, Gly47Glu, Thr59Lys, Glu61Lys, His88Arg and Ala97Ser were associated with the mixed phenotype while Leu55Arg was associated with the ophthalmic phenotype. The deletion mutation was found in a patient with a cardiac phenotype (<a href="#T3">Table 3</a>).</p>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1</strong>. Distribution of <i>TTR</i> mutations in a cohort of ATTR-CA patients from South China.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" name="Table3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>

</a>
<p><strong>Table 3</strong>. Genotype distribution in probands and family members.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb0 w100pc float_left mt15">Ala97Ser was the most common mutation in this cohort. 72.7% (8/11 cases) of patients carrying the Ala97Ser presented with evidence of heart failure at confirmed diagnosis of ATTRv cardiac amyloidosis, with 63.7% (7/11) having NYHAIII/IV (<a href="#T1">Table 1</a>). All patients with Ala97Ser mutations initially presented with neurological dysfunction, but cardiac symptoms followed 2&#x02013;9 years later. The median age of onset of neurological symptom related to ATTR amyloidosis in patients carrying the Ala97Ser variant was 65 (62&#x02013;67) years old and the median time from neurological symptom onset to diagnosis of ATTRv-CM was 48 (24&#x02013;102) months.</p>
<h3>Survival</h3>
<p class="mb0">During January 2016 to November 2021, 29 patients were diagnosed with hereditary ATTRv-CM and followed up at our institution. The date when symptoms related to ATTRv began, (which was 30 (12, 54) months before diagnosis of ATTR-CM), was recorded according to the patient&#x00027;s report. The mortality rate of the cohort over a median follow-up of 14 (5.75, 32.25) months was 7/29 (24%). The estimated median survival times after initial symptom onset related to ATTRv and at confirmed diagnosis of ATTRv-CM by Kaplan-Meier survival curve analysis were 131 (95%CI 88.6&#x02013;173.7) and 47.6 (95%CI 37.9&#x02013;57.4) months, respectively. According to Kaplan-Meier survival curve analysis, the estimated 3-, 5- and 10-year survival rates after symptom onset were 90%, 70% and 52.6%, respectively (<a href="#F2">Figure 2A</a>). The overall 1-year survival rate after diagnosis was 91.2%, and the 3- and 5-year survival rates were 74% and 38%, respectively (<a href="#F2">Figure 2B</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2. (A)</strong> Kaplan-Meier survival curves of data obtained from ATTR-CA symptom onset. Overall survival at 12-, 36-, 60-, and 120- months after symptom onset were 100%, 90%, 70% and 52.6%, respectively. Numbers below the plot represent the number of subjects at risk at each time point. Cumulative events refer to all-cause death. The median survival time after symptom onset was 131 (95%CI 88.6&#x02013;173.7) months. <strong>(B)</strong> Kaplan-Meier survival curves at confirmed diagnosis. Overall survival at 12-, 36-, and 60- months was 91.2%, 74%, and 38% respectively. Numbers below the plot represent the number of subjects at risk at each time point. Cumulative events refer to all-cause death. The estimated median survival time after confirmed diagnosis of ATTRv-CM was 47.6 (95%CI 37.9&#x02013;57.4) months.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mt15 w100pc float_left">For patient carrying Ala97Ser variant, survival curve analysis revealed the estimated mean survival time after symptom onset and at diagnosis were 181(95%CI 120.2, 241.8) months and 38.5 (95%CI 30.9, 46.1) months. Patient with other variants had estimated mean survival time of 102 (95%CI 73.1, 132.1) months after symptom onset and 43.9 (95%CI 31.3, 56.4) months at diagnosis. Cumulative survival rate at 150 months after symptom onset was 66.7% in Ala97Ser and 0% in other variants. The difference in survival curve for Ala97Ser and other variants at symptom onset was not significant [Breslow (Generalized Wilcoxon), &#x003C7;2 = 2.92, <i>p</i> = 0.087] (<a href="#F3">Figure 3A</a>). No significant difference was found in survival curve between patient carrying Ala97Ser and other variants at confirmed diagnosis. [Breslow (Generalized Wilcoxon), &#x003C7;2 = 0.859, <i>p</i> = 0.35] (<a href="#F3">Figure 3B</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3. (A)</strong> Comparison of Kaplan-Meier survival curves of data obtained from ATTR-CA symptom onset between patients with Ala97Ser and other variants. There was no significant difference in survival in patients with Ala97Ser and other variants [Breslow (Generalized Wilcoxon), &#x003C7;2 = 2.92, <i>p</i> = 0.087]. <strong>(B)</strong> Comparison of Kaplan-Meier survival curves at confirmed diagnosis between patients with Ala97Ser and other variants. Survival after diagnosis was not significantly different in patients with Ala97Ser and other variants [Breslow (Generalized Wilcoxon), &#x003C7;2 = 0.859, <i>p</i> = 0.35]. <strong>(C)</strong> Kaplan-Meier survival curve for patients grouped by NAC stage at diagnosis. Patients with NAC stage II/III disease had worse survival than those with NAC stage I disease [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, <i>p</i> = 0.03)]. The median survival time of patients in NAT stage I was 48 months (95%CI 39&#x02013;63) and the cumulative survival at 60 months was 46.7%. The median survival time of patients in NAC stage II/III was 33 months (95%CI 13.7&#x02013;55.3) and the cumulative survival at 60 months was 0%.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb0 w100pc float_left mt15">Patient at an early disease stage (NAC stage I) tended to have a lower mortality rate, with a median survival time of 48 months (95%CI 39&#x02013;63 month) and a cumulative survival rate at 60 months of 46.7% [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, <i>p</i> = 0.03]. In contrast, the median survival time of patients at a later disease stage (NAC II, III) was 33 months (95%CI 13.7&#x02013;55.3), with a cumulative survival rate at 60 months of 0% (<a href="#F3">Figure 3C</a>) All deaths were observed in patients with NYHA III-IV heart failure.</p>
<a id="h5" name="h5"></a>
<h2>Discussion</h2>
<p class="mb15">Male predominance (93%) was observed in this cohort, which was higher than previous reports on ATTRv-CM whose samples were approximately 70% (<a href="#B11">11</a>&#x02013;<a href="#B13">13</a>). This may be due to the small sample size of this study. The underlying mechanism for male predominance is unclear. The small sample size of women did not permit summarization of the sex-related clinical characteristics of ATTRv-CM. However, a recent systematic literature review on sex-related differences in transthyretin amyloid cardiomyopathy revealed that women tended to have lower interventricular septal and posterior wall thicknesses, smaller left ventricular end diastolic diameters and a higher LV ejection fraction. It was postulated that the disparity in the incidence of ATTRv-CM between sexes may be due to either the cardioprotective effects of estrogen or sex-related differences in clinical presentation or disease characteristics (<a href="#B11">11</a>).</p>
<p class="mb15">A mixed phenotype was most common presentation in this cohort (82.8%), while a predominantly cardiac phenotype and neurological phenotype was seen in 6.9% of patients each. ATTRv phenotype is associated with <i>TTR</i> mutations. While some mutations are associated with a predominantly cardiac phenotype, others are primarily related to a neurological phenotype. Previously reported common cardiac mutations (Val122Ile, leu111Met, Thr60Alr, Ile68Leu) in ATTRv were not identified in our cohort (<a href="#B14">14</a>). However, we found that non-cardiac mutations such as Asp18Asn, Ser23Asn, Glu42Gly, Gly47Glu, Thr59Lys, Glu61Lys, His88Arg and Ala97Ser were associated with a cardiac phenotype with or without neurologic symptoms. These differences in genotype-phenotype relationship may be the result of their diagnosis at different disease stages.</p>
<p class="mb0">Ten different <i>TTR</i> gene mutations, including 9 missense variants and 1 small deletion mutation, were identified. All of the missense variants have been listed as pathogenic or likely pathogenic in the TTR mutation and ClinVar databases (<a href="#T4">Table 4</a>) (<a href="#B15">15</a>&#x02013;<a href="#B23">23</a>). The missense mutations were related to the mixed phenotype. Glu61Lys, which was previously found to cause ATTR neuropathy, had never been reported in ATTR-CM. The cardiac mutations Asp18Asn and His68Arg also caused neuropathy in our study. The small deletion <i>TTR</i> mutation (c.624_632delGACTTCTCC) was located outside the coding region in exon 3 of the <i>TTR</i> gene. As the patient&#x00027;s family history could not be collected due to the limited medical records of the deceased parents, it could not be excluded that this variant of unknown significance occurred by chance in a patient with wild-type ATTR.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 4</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" name="Table4" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg" alt="www.frontiersin.org" id="T4" loading="lazy">
  </picture>

</a>
<p><strong>Table 4</strong>. Bioinformatic results of the identified missense <i>TTR</i> mutations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">In this study, 10 different mutations (<i>n</i> = 40) have been identified in probands and family members, with the most common being Ala97Ser (<i>n</i> = 16; 40%). In addition, Ala97Ser is the most common mutation in symptomatic patient (<i>n</i> = 11;37.9%). This was different in the United States, where Val1122Ile (p.Val142Ile) and Thr60Ala (p.T80A) were the most common mutations (<a href="#B14">14</a>). In European countries, Val30Met was the most frequent mutation in subjects with ATTR in the THAOS registry, followed by Ile68Leu (<a href="#B12">12</a>). This discrepancy may reflect the heterogeneity of ATTR genotypes between different countries. Ala97Ser has been previously found to be a common ATTR mutation in cohorts of Chinese patients with predominant neurologic phenotypes, including patients from north China and Taiwan. It has also been reported in Chinese Malaysians (<a href="#B10">10</a>, <a href="#B24">24</a>&#x02013;<a href="#B27">27</a>). (<a href="#SM2">Supplementary Table 2</a>) Similar with previous studies, male predominance was observed in Ala97Ser. Consistant with other studies, our study found that all patients with Ala97Ser initially presented with a predominantly neurologic phenotype in the early stages of disease. However, the proportion of patients developing cardiomyopathy as the disease progressed was higher (72.7%) than previous reports. Most Ala97Ser patients exhibited a mixed phenotype at their time of diagnosis in our study, which suggests that diagnosis was delayed until a late disease stage. This may be attributed to the difficulty with diagnosing ATTR in patients with isolated peripheral neuropathy symptoms, especially when reg flag symptoms such as carpal tunnel syndrome and lumber stenosis were rarely presented in this cohort. In this situation, family history and genetic examination were important to the early diagnosis of an ATTR patient with a neurological phenotype. On the other hand, CMR and <sup>99m</sup>Tc-PYP scintigraphy may help to identify myocardial involvement in patients who does not report symptom of heart failure due to limited physical activity caused by neuropathy.</p>
<p class="mb15">Survival is poor in patients with ATTR cardiac amyloidosis. Although survival varies by genotype, phenotype, and disease stage, most series have reported a median survival of 2.5&#x02013;3.5 years for patients with heart failure (<a href="#B8">8</a>). There was a poorer prognosis in the present work for subjects with more severe heart failure, with a 5 year survival rate of &#x0003C;20% for those with NYHA III-IV disease. Several studies have noted the prognostic role of NT-proBNP (<a href="#B28">28</a>). The NAC staging system includes NT-proBNP and eGFR and has a good prognostic accuracy (<a href="#B29">29</a>). Patients with advanced NAC stage (stage 2, 3) had a poor prognosis (median survival: 34.5 months, 3-year survival rate: 43%). More advanced NYHA classification at diagnosis also tended to predict a poor prognosis, although there was no statistical significance due to the limited sample size of our study. Phenotype, genotype, initial manifestation and severity of peripheral neuropathy as shown by PND score were not predictive in our study.</p>
<p class="mb15">The natural average life expectancy is 9 to 13 years after the symptom onset and death usually results from cardiac involvement and cachexia (<a href="#B30">30</a>). As disease modifying therapy, liver transplantation has been demonstrated to prolong survival. However, the statistics are mostly related to patients with ATTR V30M (<a href="#B31">31</a>), which was not identified in our study cohort. Different from previous two cohort studies in China, no patient received liver transplantation in our cohort because the following reasons 1) For patients with advanced heart failure, liver transplantation does not provide a complete cure for the disease due to the newly formed amyloid around the preexisting amyloid seeds (<a href="#B32">32</a>). Combining liver and heart transplantation may be a better strategy. 2) Liver transplantation is restricted by the availability of transplant organs as well as the advanced age and comorbidities of ATTR-CM patients. 3) The need for life-long immunosuppression therapy.</p>
<p class="mb15">Tafamidis, a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by China Food and Drug Administration for the treatment of inherited or wild type cardiac transthyretin amyloidosis in adult patients in 2020. However, only a few patients could afford this disease modifying therapy because the price of tafamidis was expensive (64,100<img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_n/fcvm-09-900313-i001.gif" style="float:none;margin:0" alt="yes" >/month in 2020, then reduced to 24,650<img src="https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_n/fcvm-09-900313-i001.gif" style="float:none;margin:0" alt="yes" >/month in 2021). Up to November 2021, only 9.5% (<a href="#B4">4</a>) patients received tafamidis in our cohort. Fortunately, more patients will have chance to receive this disease modifying therapy since National Health Insurance Administration has issued a national coverage decision to incorporate Tafamidis into medical insurance payouts in 2022.</p>
<p class="mb0">There are several limitations to our study. First, this was a retrospective study that included a limited sample size. Second, all probands were admitted to our cardiology department first, which results in selection bias that may not permit the description of the actual phenotype-genotype relationship. Third, nuclear scintigraphy was only used in 9 (31%) patients. Expanding the sample size and long-term follow-up of the proband patients and their genotype positive phenotype negative pedigree is needed to understand the relationship between ATTRv genotype and disease course.</p>
<a id="h6" name="h6"></a>
<h2>Conclusion</h2>
<p class="mb0">Hereditary ATTRv-CM has heterogeneous phenotypes and genotypes. Most patients had a mixed phenotype that included both cardiomyopathy and neuropathy. Ala97Ser, the most common mutation in South China, initially presented as peripheral and automatic neuropathy and progressed to heart failure at a later disease stage. The prognosis of ATTR was poor, and patients with NYHA III-IV and NAC stage 3 had the worst prognosis.</p>
<a id="h7" name="h7"></a>
<h2>Data Availability Statement</h2>
<p class="mb0">The original contributions presented in the study are included in the article/<a href="#h14">Supplementary Materials</a>, further inquiries can be directed to the corresponding author.</p>
<a id="h8" name="h8"></a>
<h2>Ethics Statement</h2>
<p class="mb0">The studies involving human participants were reviewed and approved by the Ethics Committee of Second Xiangya Hospital. The patients/participants provided their written informed consent to participate in this study.</p>
<a id="h9" name="h9"></a>
<h2>Author Contributions</h2>
<p class="mb0">SW wrote the protocol, evaluated cardiac involvement, analyzed the results and wrote the manuscript. WP and MP collected the data. LM did the TTR sequencing and analyzed the gene data. DP conceived of the study. BY revised the manuscript and provided guidance for the study. SW, BY, DP, SW, DH, YY, and JH evaluated the patients and made the clinical diagnosis for each patient. All authors contributed to the article and approved the submitted version.</p>
<a id="h10" name="h10"></a>
<h2>Funding</h2>
<p class="mb0">This work was supported by grants from the National Nature Science Foundation Youth Project (81600359) and the National Nature Science Foundation General Project (81870336).</p>
<a id="h11" name="h11"></a>
<h2>Conflict of Interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h12" name="h12"></a>
<h2>Publisher&#x00027;s Note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
<a id="h13" name="h13"></a>
<h2>Acknowledgments</h2>
<p class="mb0">We would like to thank all of the participating families and investigators for their important contributions to this study. Additional investigators contributing to analysis Na Liu.</p>
<a id="h14" name="h14"></a>
<h2>Supplementary Material</h2>
<p class="mb0" id="SM1">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fcvm.2022.900313/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcvm.2022.900313/full#supplementary-material</a></p>
<a id="h15" name="h15"></a>
<h2>References</h2>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. <i>Lancet.</i> (2016) 387:2641&#x02013;54. doi: 10.1016/S0140-6736(15)01274-X</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26719234" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S0140-6736(15)01274-X" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AD+Wechalekar&#x00026;author=JD+Gillmore&#x00026;author=PN+Hawkins+&#x00026;publication_year=2016&#x00026;title=Systemic+amyloidosis&#x00026;journal=Lancet.&#x00026;volume=387&#x00026;pages=2641-54" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. <i>Cardiol Ther.</i> (2021) 10:289&#x02013;311. doi: 10.1007/s40119-021-00222-w</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34089151" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s40119-021-00222-w" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Koike&#x00026;author=T+Okumura&#x00026;author=T+Murohara&#x00026;author=M+Katsuno+&#x00026;publication_year=2021&#x00026;title=Multidisciplinary+approaches+for+transthyretin+amyloidosis&#x00026;journal=Cardiol+Ther.&#x00026;volume=10&#x00026;pages=289-311" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med.</i> (2018) 379:1007&#x02013;16. doi: 10.1056/NEJMoa1805689</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34788394" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1805689" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MS+Maurer&#x00026;author=JH+Schwartz&#x00026;author=B+Gundapaneni&#x00026;author=PM+Elliott&#x00026;author=G+Merlini&#x00026;author=M+Waddington-Cruz+&#x00026;publication_year=2018&#x00026;title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=1007-16" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. <i>N Engl J Med.</i> (2018) 379:22&#x02013;31. doi: 10.1056/NEJMoa1716793</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32286934" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1716793" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MD+Benson&#x00026;author=M+Waddington-Cruz&#x00026;author=JL+Berk&#x00026;author=M+Polydefkis&#x00026;author=PJ+Dyck&#x00026;author=AK+Wang+&#x00026;publication_year=2018&#x00026;title=Inotersen+treatment+for+patients+with+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=22-31" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Adams D, Gonzalez-Duarte A, O&#x00027;Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <i>N Engl J Med.</i> (2018) 379:11&#x02013;21. doi: 10.1056/NEJMoa1716153</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29972753" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1716153" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=A+Gonzalez-Duarte&#x00026;author=WD+O&#x00027;Riordan&#x00026;author=CC+Yang&#x00026;author=M+Ueda&#x00026;author=AV+Kristen+&#x00026;publication_year=2018&#x00026;title=Patisiran,+an+RNAi+therapeutic,+for+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=11-21" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. <i>Nucleic Acids Res.</i> (2018) 46:D1062&#x02013;D7. doi: 10.1093/nar/gkx1153</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29165669" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkx1153" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Landrum&#x00026;author=JM+Lee&#x00026;author=M+Benson&#x00026;author=GR+Brown&#x00026;author=C+Chao&#x00026;author=S+Chitipiralla+&#x00026;publication_year=2018&#x00026;title=ClinVar%3A+improving+access+to+variant+interpretations+and+supporting+evidence&#x00026;journal=Nucleic+Acids+Res.&#x00026;volume=46&#x00026;pages=D1062-D7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Carry BJ, Young K, Fielden S, Kelly MA, Sturm AC, Avila JD, et al. Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records. <i>JACC CardioOncol.</i> (2021) 3:550&#x02013;61. doi: 10.1016/j.jaccao.2021.07.002</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34746851" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jaccao.2021.07.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BJ+Carry&#x00026;author=K+Young&#x00026;author=S+Fielden&#x00026;author=MA+Kelly&#x00026;author=AC+Sturm&#x00026;author=JD+Avila+&#x00026;publication_year=2021&#x00026;title=Genomic+screening+for+pathogenic+transthyretin+variants+finds+evidence+of+underdiagnosed+amyloid+cardiomyopathy+from+health+records&#x00026;journal=JACC+CardioOncol.&#x00026;volume=3&#x00026;pages=550-61" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. <i>Circulation.</i> (2012) 126:1286&#x02013;300. doi: 10.1161/CIRCULATIONAHA.111.078915</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22949539" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1161/CIRCULATIONAHA.111.078915" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FL+Ruberg&#x00026;author=JL+Berk+&#x00026;publication_year=2012&#x00026;title=Transthyretin+(TTR)+cardiac+amyloidosis&#x00026;journal=Circulation.&#x00026;volume=126&#x00026;pages=1286-300" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. He S, Tian Z, Guan H, Li J, Fang Q, Zhang S. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. <i>Orphanet J Rare Dis.</i> (2019) 14:251. doi: 10.1186/s13023-019-1235-x</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31718691" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13023-019-1235-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+He&#x00026;author=Z+Tian&#x00026;author=H+Guan&#x00026;author=J+Li&#x00026;author=Q+Fang&#x00026;author=S+Zhang+&#x00026;publication_year=2019&#x00026;title=Clinical+characteristics+and+prognosis+of+Chinese+patients+with+hereditary+transthyretin+amyloid+cardiomyopathy&#x00026;journal=Orphanet+J+Rare+Dis.&#x00026;volume=14&#x00026;pages=251" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B10" id="B10"></a> 10. Du K, Li F, Wang H, Miao Y, Lv H, Zhang W, et al. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. <i>Ann Clin Transl Neurol.</i> (2021) 8:831&#x02013;41. doi: 10.1002/acn3.51328</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33739616" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/acn3.51328" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Du&#x00026;author=F+Li&#x00026;author=H+Wang&#x00026;author=Y+Miao&#x00026;author=H+Lv&#x00026;author=W+Zhang+&#x00026;publication_year=2021&#x00026;title=Hereditary+transthyretin+amyloidosis+in+mainland+China%3A+a+unicentric+retrospective+study&#x00026;journal=Ann+Clin+Transl+Neurol.&#x00026;volume=8&#x00026;pages=831-41" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B11" id="B11"></a> 11. Bruno M, Castano A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. <i>Heart Fail Rev.</i> (2021) 26:35&#x02013;45. doi: 10.1007/s10741-020-10010-8</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32794090" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10741-020-10010-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Bruno&#x00026;author=A+Castano&#x00026;author=A+Burton&#x00026;author=JL+Grodin+&#x00026;publication_year=2021&#x00026;title=Transthyretin+amyloid+cardiomyopathy+in+women%3A+frequency,+characteristics,+and+diagnostic+challenges&#x00026;journal=Heart+Fail+Rev.&#x00026;volume=26&#x00026;pages=35-45" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B12" id="B12"></a> 12. Damy T, Kristen AV, Suhr OB, Maurer MS, Plante-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). <i>Eur Heart J.</i> (2019). doi: 10.1093/eurheartj/ehz173</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30938420" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehz173" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Damy&#x00026;author=AV+Kristen&#x00026;author=OB+Suhr&#x00026;author=MS+Maurer&#x00026;author=V+Plante-Bordeneuve&#x00026;author=CR+Yu+&#x00026;publication_year=2019&#x00026;title=Transthyretin+cardiac+amyloidosis+in+continental+western+Europe%3A+an+insight+through+the+Transthyretin+Amyloidosis+Outcomes+Survey+(THAOS)&#x00026;journal=Eur+Heart+J." target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B13" id="B13"></a> 13. Batra J, Rosenblum H, Defilippis EM, Griffin JM, Saith SE, Gamino D, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to val122ile mutation: insights from noninvasive pressure-volume analysis. <i>J Card Fail.</i> (2021) 27:67&#x02013;74. doi: 10.1016/j.cardfail.2020.08.007</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32829019" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cardfail.2020.08.007" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Batra&#x00026;author=H+Rosenblum&#x00026;author=EM+Defilippis&#x00026;author=JM+Griffin&#x00026;author=SE+Saith&#x00026;author=D+Gamino+&#x00026;publication_year=2021&#x00026;title=Sex+differences+in+the+phenotype+of+transthyretin+cardiac+amyloidosis+due+to+val122ile+mutation%3A+insights+from+noninvasive+pressure-volume+analysis&#x00026;journal=J+Card+Fail.&#x00026;volume=27&#x00026;pages=67-74" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B14" id="B14"></a> 14. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol.</i> (2019) 73:2872&#x02013;91. doi: 10.1016/j.jacc.2019.04.003</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31171094" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2019.04.003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FL+Ruberg&#x00026;author=M+Grogan&#x00026;author=M+Hanna&#x00026;author=JW+Kelly&#x00026;author=MS+Maurer+&#x00026;publication_year=2019&#x00026;title=Transthyretin+amyloid+cardiomyopathy%3A+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol.&#x00026;volume=73&#x00026;pages=2872-91" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B15" id="B15"></a> 15. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. <i>Amyloid.</i> (2003) 10:160&#x02013;84. doi: 10.3109/13506120308998998</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/14640030" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/13506120308998998" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LH+Connors&#x00026;author=A+Lim&#x00026;author=T+Prokaeva&#x00026;author=VA+Roskens&#x00026;author=CE+Costello+&#x00026;publication_year=2003&#x00026;title=Tabulation+of+human+transthyretin+(TTR)+variants,+2003&#x00026;journal=Amyloid.&#x00026;volume=10&#x00026;pages=160-84" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B16" id="B16"></a> 16. Connors LH, Theberge R, Skare J, Costello CE, Falk RH, Skinner M, et al. New transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient. <i>Amyloid.</i> (1999) 6:114&#x02013;8. doi: 10.3109/13506129909007311</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10439117" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/13506129909007311" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LH+Connors&#x00026;author=R+Theberge&#x00026;author=J+Skare&#x00026;author=CE+Costello&#x00026;author=RH+Falk&#x00026;author=M+Skinner+&#x00026;publication_year=1999&#x00026;title=New+transthyretin+variant+(Ser23Asn)+associated+with+familial+amyloidosis+in+a+Portuguese+patient&#x00026;journal=Amyloid.&#x00026;volume=6&#x00026;pages=114-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B17" id="B17"></a> 17. Ueno S, Uemichi T, Takahashi N, Soga F, Yorifuji S, Tarui S. Two novel variants of transthyretin identified in Japanese cases with familial amyloidotic polyneuropathy: transthyretin (Glu42 to Gly) and transthyretin (Ser50 to Arg). <i>Biochem Biophys Res Commun.</i> (1990) 169:1117&#x02013;21. doi: 10.1016/0006-291X(90)92011-N</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2363717" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/0006-291X(90)92011-N" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Ueno&#x00026;author=T+Uemichi&#x00026;author=N+Takahashi&#x00026;author=F+Soga&#x00026;author=S+Yorifuji&#x00026;author=S+Tarui+&#x00026;publication_year=1990&#x00026;title=Two+novel+variants+of+transthyretin+identified+in+Japanese+cases+with+familial+amyloidotic+polyneuropathy%3A+transthyretin+(Glu42+to+Gly)+and+transthyretin+(Ser50+to+Arg)&#x00026;journal=Biochem+Biophys+Res+Commun.&#x00026;volume=169&#x00026;pages=1117-21" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B18" id="B18"></a> 18. Pelo E, Da Prato L, Ciaccheri M, Castelli G, Gori F, Pizzi A, et al. Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred. <i>Amyloid.</i> (2002) 9:35&#x02013;41. doi: 10.3109/13506120209072443</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12000196" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/13506120209072443" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Pelo&#x00026;author=L+Da+Prato&#x00026;author=M+Ciaccheri&#x00026;author=G+Castelli&#x00026;author=F+Gori&#x00026;author=A+Pizzi+&#x00026;publication_year=2002&#x00026;title=Familial+amyloid+polyneuropathy+with+genetic+anticipation+associated+to+a+gly47glu+transthyretin+variant+in+an+Italian+kindred&#x00026;journal=Amyloid.&#x00026;volume=9&#x00026;pages=35-41" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B19" id="B19"></a> 19. Long D, Zeng J, Wu LQ, Tang LS, Wang HL, Wang H. Vitreous amyloidosis in two large mainland Chinese kindreds resulting from transthyretin variant Lys35Thr and Leu55Arg. <i>Ophthalmic Genet.</i> (2012) 33:28&#x02013;33. doi: 10.3109/13816810.2011.599356</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21843040" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/13816810.2011.599356" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Long&#x00026;author=J+Zeng&#x00026;author=LQ+Wu&#x00026;author=LS+Tang&#x00026;author=HL+Wang&#x00026;author=H+Wang+&#x00026;publication_year=2012&#x00026;title=Vitreous+amyloidosis+in+two+large+mainland+Chinese+kindreds+resulting+from+transthyretin+variant+Lys35Thr+and+Leu55Arg&#x00026;journal=Ophthalmic+Genet.&#x00026;volume=33&#x00026;pages=28-33" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B20" id="B20"></a> 20. Saraiva MJ. Transthyretin mutations in health and disease. <i>Hum Mutat.</i> (1995) 5:191&#x02013;6. </p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?author=MJ+Saraiva+&#x00026;publication_year=1995&#x00026;title=Transthyretin+mutations+in+health+and+disease&#x00026;journal=Hum+Mutat.&#x00026;volume=5&#x00026;pages=191-6" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B21" id="B21"></a> 21. Shiomi K, Nakazato M, Matsukura S, Ohnishi A, Hatanaka H, Tsuji S, et al. A basic transthyretin variant (Glu61&#x02013;&#x0003E;Lys) causes familial amyloidotic polyneuropathy: protein and DNA sequencing and PCR-induced mutation restriction analysis. <i>Biochem Biophys Res Commun.</i> (1993) 194:1090&#x02013;6. doi: 10.1006/bbrc.1993.1933</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/8352764" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1006/bbrc.1993.1933" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Shiomi&#x00026;author=M+Nakazato&#x00026;author=S+Matsukura&#x00026;author=A+Ohnishi&#x00026;author=H+Hatanaka&#x00026;author=S+Tsuji+&#x00026;publication_year=1993&#x00026;title=A+basic+transthyretin+variant+(Glu61&#x02013;&#x0003E;Lys)+causes+familial+amyloidotic+polyneuropathy%3A+protein+and+DNA+sequencing+and+PCR-induced+mutation+restriction+analysis&#x00026;journal=Biochem+Biophys+Res+Commun.&#x00026;volume=194&#x00026;pages=1090-6" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B22" id="B22"></a> 22. Holmgren G, Hellman U, Anan I, Lundgren HE, Jonasson J, Stafberg C, et al. Cardiomyopathy in Swedish patients with the Gly53Glu and His88Arg transthyretin variants. <i>Amyloid.</i> (2005) 12:184&#x02013;8. doi: 10.1080/13506120500223126</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16194874" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/13506120500223126" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Holmgren&#x00026;author=U+Hellman&#x00026;author=I+Anan&#x00026;author=HE+Lundgren&#x00026;author=J+Jonasson&#x00026;author=C+Stafberg+&#x00026;publication_year=2005&#x00026;title=Cardiomyopathy+in+Swedish+patients+with+the+Gly53Glu+and+His88Arg+transthyretin+variants&#x00026;journal=Amyloid.&#x00026;volume=12&#x00026;pages=184-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B23" id="B23"></a> 23. Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. <i>Amyloid.</i> (1999) 6:282&#x02013;8. doi: 10.3109/13506129909007341</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10611950" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3109/13506129909007341" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Tachibana&#x00026;author=T+Tokuda&#x00026;author=K+Yoshida&#x00026;author=T+Taketomi&#x00026;author=M+Nakazato&#x00026;author=YF+Li+&#x00026;publication_year=1999&#x00026;title=Usefulness+of+MALDI%2FTOF+mass+spectrometry+of+immunoprecipitated+serum+variant+transthyretin+in+the+diagnosis+of+familial+amyloid+polyneuropathy&#x00026;journal=Amyloid.&#x00026;volume=6&#x00026;pages=282-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B24" id="B24"></a> 24. Hsu HC, Liao MF, Hsu JL, Lo AL, Kuo HC Lyu RK, et al. Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese. <i>BMC Neurol.</i> (2017) 17:178. doi: 10.1186/s12883-017-0957-4</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28882124" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12883-017-0957-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HC+Hsu&#x00026;author=MF+Liao&#x00026;author=JL+Hsu&#x00026;author=AL+Lo&#x00026;author=RK+Kuo+HC+Lyu+&#x00026;publication_year=2017&#x00026;title=Phenotypic+expressions+of+hereditary+Transthyretin+Ala97Ser+related+Amyloidosis+(ATTR)+in+Taiwanese&#x00026;journal=BMC+Neurol.&#x00026;volume=17&#x00026;pages=178" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B25" id="B25"></a> 25. Low SC, Tan CY, Md Sari NA, Ahmad-Annuar A, Wong KT, Lin KP, et al. Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy. <i>Amyloid.</i> (2019) 26:7&#x02013;8. doi: 10.1080/13506129.2019.1582479</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31343308" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/13506129.2019.1582479" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SC+Low&#x00026;author=CY+Tan&#x00026;author=NA+Md+Sari&#x00026;author=A+Ahmad-Annuar&#x00026;author=KT+Wong&#x00026;author=KP+Lin+&#x00026;publication_year=2019&#x00026;title=Ala97Ser+mutation+is+common+among+ethnic+Chinese+Malaysians+with+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=Amyloid.&#x00026;volume=26&#x00026;pages=7-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B26" id="B26"></a> 26. Liu YT, Lee YC, Yang CC, Chen ML, Lin KP. Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression. <i>J Neurol Sci.</i> (2008) 267:91&#x02013;9. doi: 10.1016/j.jns.2007.10.011</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18022643" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jns.2007.10.011" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YT+Liu&#x00026;author=YC+Lee&#x00026;author=CC+Yang&#x00026;author=ML+Chen&#x00026;author=KP+Lin+&#x00026;publication_year=2008&#x00026;title=Transthyretin+Ala97Ser+in+Chinese-Taiwanese+patients+with+familial+amyloid+polyneuropathy%3A+genetic+studies+and+phenotype+expression&#x00026;journal=J+Neurol+Sci.&#x00026;volume=267&#x00026;pages=91-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B27" id="B27"></a> 27. Chao CC, Huang CM, Chiang HH, Luo KR, Kan HW, Yang NC, et al. Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates. <i>Ann Neurol.</i> (2015) 78:272&#x02013;83. doi: 10.1002/ana.24438</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25973863" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ana.24438" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CC+Chao&#x00026;author=CM+Huang&#x00026;author=HH+Chiang&#x00026;author=KR+Luo&#x00026;author=HW+Kan&#x00026;author=NC+Yang+&#x00026;publication_year=2015&#x00026;title=Sudomotor+innervation+in+transthyretin+amyloid+neuropathy%3A+Pathology+and+functional+correlates&#x00026;journal=Ann+Neurol.&#x00026;volume=78&#x00026;pages=272-83" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B28" id="B28"></a> 28. Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>Eur J Heart Fail.</i> (2021) 23:217&#x02013;30. doi: 10.1002/ejhf.2113</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33527656" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ejhf.2113" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Castiglione&#x00026;author=M+Franzini&#x00026;author=A+Aimo&#x00026;author=A+Carecci&#x00026;author=CM+Lombardi&#x00026;author=C+Passino+&#x00026;publication_year=2021&#x00026;title=Use+of+biomarkers+to+diagnose+and+manage+cardiac+amyloidosis&#x00026;journal=Eur+J+Heart+Fail.&#x00026;volume=23&#x00026;pages=217-30" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B29" id="B29"></a> 29. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. a position statement of the European Society of cardiology working group on myocardial and pericardial diseases. <i>Eur J Heart Fail.</i> (2021) 23:512&#x02013;26. doi: 10.1002/ejhf.2140</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/33826207" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ejhf.2140" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P+Garcia-Pavia&#x00026;author=C+Rapezzi&#x00026;author=Y+Adler&#x00026;author=M+Arad&#x00026;author=C+Basso&#x00026;author=A+Brucato+&#x00026;publication_year=2021&#x00026;title=Diagnosis+and+treatment+of+cardiac+amyloidosis.+a+position+statement+of+the+European+Society+of+cardiology+working+group+on+myocardial+and+pericardial+diseases&#x00026;journal=Eur+J+Heart+Fail.&#x00026;volume=23&#x00026;pages=512-26" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B30" id="B30"></a> 30. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. <i>Liver Transpl.</i> (2000) 6:263&#x02013;76. doi: 10.1053/lv.2000.6145</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10827225" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1053/lv.2000.6145" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=OB+Suhr&#x00026;author=G+Herlenius&#x00026;author=S+Friman&#x00026;author=BG+Ericzon+&#x00026;publication_year=2000&#x00026;title=Liver+transplantation+for+hereditary+transthyretin+amyloidosis&#x00026;journal=Liver+Transpl.&#x00026;volume=6&#x00026;pages=263-76" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B31" id="B31"></a> 31. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. <i>Liver Transpl.</i> (2015) 21:282&#x02013;92. doi: 10.1002/lt.24058</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25891323" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/lt.24058" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Carvalho&#x00026;author=A+Rocha&#x00026;author=L+Lobato+&#x00026;publication_year=2015&#x00026;title=Liver+transplantation+in+transthyretin+amyloidosis%3A+issues+and+challenges&#x00026;journal=Liver+Transpl.&#x00026;volume=21&#x00026;pages=282-92" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B32" id="B32"></a> 32. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. <i>Neurology.</i> (2010) 75:324&#x02013;7. doi: 10.1212/WNL.0b013e3181ea15d4</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20660862" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1212/WNL.0b013e3181ea15d4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JJ+Liepnieks&#x00026;author=LQ+Zhang&#x00026;author=MD+Benson+&#x00026;publication_year=2010&#x00026;title=Progression+of+transthyretin+amyloid+neuropathy+after+liver+transplantation&#x00026;journal=Neurology.&#x00026;volume=75&#x00026;pages=324-7" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords:</span> hereditary, transthyretin amyloidosis, cardiomyopathy, prognosis, China</p>
<p><span>Citation:</span> Wang S, Peng W, Pang M, Mao L, Peng D, Yu B, Wu S, Hu D, Yang Y, He J and Ouyang M (2022) Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China. <i>Front. Cardiovasc. Med.</i> 9:900313. doi: 10.3389/fcvm.2022.900313</p>
<p id="timestamps"><span>Received:</span> 20 March 2022; <span>Accepted:</span> 07 June 2022;<br> <span>Published:</span> 27 June 2022.</p>
<div><p>Edited by:</p> <a href="http://loop.frontiersin.org/people/1401135/overview">Jeffrey Shi Kai Chan</a>, Cardiovascular Analytics Group, Hong Kong SAR, China</div>
<div><p>Reviewed by:</p> <a href="http://loop.frontiersin.org/people/788222/overview">Concetta Zito</a>, University of Messina, Italy<br> <a href="http://loop.frontiersin.org/people/820312/overview">Marcus V. Pinto</a>, Mayo Clinic, United States</div>
<p><span>Copyright</span> &#x000A9; 2022 Wang, Peng, Pang, Mao, Peng, Yu, Wu, Hu, Yang, He and Ouyang. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Daoquan Peng, <a id="encmail">cGVuZ2RxQGNzdS5lZHUuY24=</a></p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fcvm.2022.900313" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">4,7K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,4K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">13</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/900313#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fcvm.2022.900313" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fcvm.2022.900313" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/1401135/overview" data-event="editorInfo-a-jeffreyShiKaiChan" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">J</span><span class="notranslate">S</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Jeffrey Shi Kai  Chan</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Cardiovascular Analytics Group, Hong Kong, SAR China</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/788222/overview" data-event="editorInfo-a-concettaZito" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">C</span><span class="notranslate">Z</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Concetta  Zito</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Messina, Italy</div></div></a><a href="https://loop.frontiersin.org/people/820312/overview" data-event="editorInfo-a-marcusVPinto" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">V</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Marcus  V Pinto</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Mayo Clinic, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Conclusion</a></li>
<li><a href="#h7">Data Availability Statement</a></li>
<li><a href="#h8">Ethics Statement</a></li>
<li><a href="#h9">Author Contributions</a></li>
<li><a href="#h10">Funding</a></li>
<li><a href="#h11">Conflict of Interest</a></li>
<li><a href="#h12">Publisher&#x00027;s Note</a></li>
<li><a href="#h13">Acknowledgments</a></li>
<li><a href="#h14">Supplementary Material</a></li>
<li><a href="#h15">References</a></li>
</ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fcvm.2022.900313" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full",["Reactive",16],{"main":17,"user":529,"article":530,"articleHub":852,"mainHeader":856},{"ibar":18,"footer":292,"newsletterComponent":-1,"snackbarItem":374,"toggleShowSnackbar":375,"contentfulJournal":376,"graphJournal":430,"settingsFeaturesSwitchers":434,"templateToggleBanner":435,"tenantConfig":494},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":223,"aboutJournal":224,"mainLinks":273,"journalLinks":280,"helpCenterLink":289},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=103&specialtyid=0&entitytype=2&entityid=755",{"id":115,"name":116,"slug":117,"sections":118},755,"Frontiers in Cardiovascular Medicine","cardiovascular-medicine",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211,215,219],{"id":120,"name":121,"slug":122},3114,"Aortic Surgery and Endovascular Repair Archive","aortic-surgery-and-endovascular-repair-archive",{"id":124,"name":125,"slug":126},857,"Atherosclerosis and Vascular Medicine","atherosclerosis-and-vascular-medicine",{"id":128,"name":129,"slug":130},849,"Cardiac Rhythmology","cardiac-rhythmology",{"id":132,"name":133,"slug":134},1513,"Cardio-Oncology","cardio-oncology",{"id":136,"name":137,"slug":138},3205,"Cardioneurology","cardioneurology",{"id":140,"name":141,"slug":142},855,"Cardiovascular Biologics and Regenerative Medicine","cardiovascular-biologics-and-regenerative-medicine",{"id":144,"name":145,"slug":146},802,"Cardiovascular Epidemiology and Prevention","cardiovascular-epidemiology-and-prevention",{"id":148,"name":149,"slug":150},847,"Cardiovascular Genetics and Systems Medicine","cardiovascular-genetics-and-systems-medicine",{"id":152,"name":153,"slug":154},813,"Cardiovascular Imaging","cardiovascular-imaging",{"id":156,"name":157,"slug":158},959,"Cardiovascular Metabolism","cardiovascular-metabolism",{"id":160,"name":161,"slug":162},3689,"Cardiovascular Nursing","cardiovascular-nursing",{"id":164,"name":165,"slug":166},3150,"Cardiovascular Pharmacology and Drug Discovery","cardiovascular-pharmacology-and-drug-discovery",{"id":168,"name":169,"slug":170},816,"Cardiovascular Surgery","cardiovascular-surgery",{"id":172,"name":173,"slug":174},3149,"Clinical and Translational Cardiovascular Medicine","clinical-and-translational-cardiovascular-medicine",{"id":176,"name":177,"slug":178},2001,"Coronary Artery Disease","coronary-artery-disease",{"id":180,"name":181,"slug":182},850,"General Cardiovascular Medicine","general-cardiovascular-medicine",{"id":184,"name":185,"slug":186},851,"Heart Failure and Transplantation","heart-failure-and-transplantation",{"id":188,"name":189,"slug":190},1829,"Heart Valve Disease","heart-valve-disease",{"id":192,"name":193,"slug":194},820,"Hypertension","hypertension",{"id":196,"name":197,"slug":198},3206,"Intensive Care Cardiovascular Medicine","intensive-care-cardiovascular-medicine",{"id":200,"name":201,"slug":202},2112,"Lipids in Cardiovascular Disease","lipids-in-cardiovascular-disease",{"id":204,"name":205,"slug":206},613,"Pediatric Cardiology","pediatric-cardiology",{"id":208,"name":209,"slug":210},3415,"Precision Cardiology","precision-cardiology",{"id":212,"name":213,"slug":214},1832,"Sex and Gender in Cardiovascular Medicine","sex-and-gender-in-cardiovascular-medicine",{"id":216,"name":217,"slug":218},1325,"Structural Interventional Cardiology","structural-interventional-cardiology",{"id":220,"name":221,"slug":222},2018,"Thrombosis and Haemostasis","thrombosis-and-haemostasis","Sections",[225,249],{"title":226,"links":227},"Scope",[228,231,234,237,240,243,246],{"text":229,"url":230,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors",{"text":232,"url":233,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope",{"text":235,"url":236,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts",{"text":238,"url":239,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission",{"text":241,"url":242,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open",{"text":244,"url":245,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement",{"text":247,"url":248,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality",{"title":250,"links":251},"For authors",[252,255,258,261,264,267,270],{"text":253,"url":254,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit",{"text":256,"url":257,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types",{"text":259,"url":260,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines",{"text":262,"url":263,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines",{"text":265,"url":266,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees",{"text":268,"url":269,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist",{"text":271,"url":272,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office",[274,277],{"text":275,"url":276,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":278,"url":279,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[281,284,286],{"text":282,"url":283,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":285,"target":27,"ariaLabel":28},"research-topics",{"text":287,"url":288,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":290,"url":291,"target":77,"ariaLabel":290},"Help center","https://helpcenter.frontiersin.org",{"blocks":293,"socialLinks":347,"copyright":371,"termsAndConditionsUrl":372,"privacyPolicyUrl":373},[294,308,318,332],{"title":295,"links":296},"Guidelines",[297,299,302,305,307],{"text":259,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":300,"url":301,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":303,"url":304,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":262,"url":306,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":309,"links":310},"Explore",[311,312,315,317],{"text":282,"url":279,"target":27,"ariaLabel":28},{"text":313,"url":314,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":316,"url":276,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":319,"links":320},"Outreach",[321,324,327,331],{"text":322,"url":92,"target":77,"ariaLabel":323},"Frontiers Forum ","Frontiers Forum website",{"text":325,"url":326,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":328,"url":329,"target":77,"ariaLabel":330},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":333,"links":334},"Connect",[335,336,340,343,346],{"text":290,"url":291,"target":77,"ariaLabel":290},{"text":337,"url":338,"target":77,"ariaLabel":339},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":341,"url":111,"target":27,"ariaLabel":342},"Contact us ","Subscribe to newsletter",{"text":344,"url":345,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[348,356,361,366],{"link":349,"type":352,"color":353,"icon":354,"size":355,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":350},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":357,"type":352,"color":353,"icon":360,"size":355,"hiddenText":13},{"text":358,"url":359,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":362,"type":352,"color":353,"icon":365,"size":355,"hiddenText":13},{"text":363,"url":364,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":367,"type":352,"color":353,"icon":370,"size":355,"hiddenText":13},{"text":368,"url":369,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":377,"identifier":115,"name":116,"slug":117,"banner":378,"description":423,"mission":424,"palette":425,"impactFactor":426,"citeScore":427,"citations":428,"showTagline":28,"twitter":429},"Journal",[379],{"id":380,"src":381,"name":382,"type":383,"width":384,"height":385,"idHash":386,"archive":387,"brandId":388,"limited":387,"fileSize":389,"isPublic":390,"original":391,"copyright":19,"extension":392,"thumbnails":394,"dateCreated":402,"description":19,"orientation":403,"userCreated":404,"watermarked":387,"dateModified":402,"datePublished":405,"ecsArchiveFiles":406,"propertyOptions":407,"property_Channel":412,"property_Sub-Type":414,"property_Asset_Type":416,"activeOriginalFocusPoint":418,"property_Office_Department":421},"0E097865-0E34-4E8F-84C1727DD698619A","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/webimage-26D7D41D-2261-478D-A085B8C607B76316.png","FCVM_Main Visual_Red_Website","image",4928,3264,"3d4ead6d0ff9ddd0",0,"22C10171-81B3-4DA6-99342F272A32E8BB",996380,1,"https://brand.frontiersin.org/m/3d4ead6d0ff9ddd0/original/FCVM_Main-Visual_Red_Website.jpg",[393],"jpg",{"mini":395,"thul":396,"webimage":381,"Guidelines":397,"WebsiteJpg_XL":398,"WebsiteWebP_L":399,"WebsiteWebP_M":400,"WebsiteWebP_XL":401},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/mini-D3B4A072-4891-48D0-A1517AD0B515C67C.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/thul-862A7E98-77F8-406C-935A26D93CF11874.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/Guidelines-FCVM_Main Visual_Red_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteJpg_XL-FCVM_Main Visual_Red_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_L-FCVM_Main Visual_Red_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_M-FCVM_Main Visual_Red_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_XL-FCVM_Main Visual_Red_Website.webp","2022-06-27T09:59:15Z","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[408,409,410,411],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[413],"frontiersin_org",[415],"Main_Visual",[417],"Photography",{"x":419,"y":420},2464,1632,[422],"Publishing","Multidisciplinary journal publishing peer-reviewed research across basic, translational, and clinical cardiovascular medicine.","\u003Cp>Frontiers in Cardiovascular Medicine is a multidisciplinary journal that publishes research articles across basic, translational, and clinical cardiovascular medicine.\u003C/p>\n\n\u003Cp>Led by Field Chief Editors Dr Masanori Aikawa (Brigham Womens Hospital, USA) and Dr Hendrik Tevaearai Stahel (University Hospital of Bern, Switzerland) Frontiers in Cardiovascular Medicine covers all aspects of cardiovascular medicine, with an emphasis on studies that challenge the status quo of treatments and practices or facilitate the translation of scientific advances into the clinic.\u003C/p>\n\n\u003Cp>Topics include, but are not limited to:\u003C/p>\n\n\u003Cdiv>&bull; atherosclerosis and vascular medicine\u003C/div>\n\u003Cdiv>&bull; cardiac rhythmology\u003C/div>\n\u003Cdiv>&bull; cardio-oncology\u003C/div>\n\u003Cdiv>&bull; cardioneurology\u003C/div>\n\u003Cdiv>&bull; cardiovascular epidemiology and prevention\u003C/div>\n\u003Cdiv>&bull; cardiovascular genetics and systems medicine\u003C/div>\n\u003Cdiv>&bull; cardiovascular imaging\u003C/div>\n\u003Cdiv>&bull; cardiovascular metabolism\u003C/div>\n\u003Cdiv>&bull; cardiovascular nursing\u003C/div>\n\u003Cdiv>&bull; cardiovascular pharmacology and drug discovery\u003C/div>\n\u003Cdiv>&bull; cardiovascular surgery\u003C/div>\n\u003Cdiv>&bull; clinical and translational cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; coronary artery disease\u003C/div>\n\u003Cdiv>&bull; general cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; heart failure and transplantation\u003C/div>\n\u003Cdiv>&bull; heart valve disease\u003C/div>\n\u003Cdiv>&bull; hypertension\u003C/div>\n\u003Cdiv>&bull; intensive care cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; lipids in cardiovascular disease\u003C/div>\n\u003Cdiv>&bull; pediatric cardiology\u003C/div>\n\u003Cdiv>&bull; precision cardiology\u003C/div>\n\u003Cdiv>&bull; sex and gender in cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; structural interventional cardiology\u003C/div>\n\u003Cdiv>&bull; thrombosis and haemostasis.\u003C/div>\n\u003Cbr>\n\u003Cp>Both fundamental mechanistic studies of cardiovascular disease and translational research that can bring new discoveries to patients quickly are welcome. The editors are especially interested in submissions that employ a systems approach driven by data science. \n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, such as NHANES or Mendelian Randomization studies, must include appropriate validation. The journal is not considering bibliometric studies. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered. \n\n\u003Cp>In particular, the journal welcomes submissions that support and advance the UNs Sustainable Development Goal (SDG), notably SDG#3: Ensure healthy lives and promote well-being for all at all ages.\u003C/p> \n\n\u003Cp>Frontiers in Cardiovascular Medicine is committed to advancing developments in the field of cardiovascular medicine by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","red","3.6","2.6","110175","@FrontCVMedicine",{"id":115,"name":116,"slug":117,"abbreviation":431,"isOnline":13,"isOpenForSubmissions":13,"citeScore":432,"impactFactor":433},"fcvm",5.5,2.9,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":375},{"isPublic":13,"allowCompanyUsers":375,"whiteListEmails":436,"enableAllJournals":13,"whiteListJournals":458},[437,438,439,440,441,442,443,444,445,442,446,447,448,449,450,451,452,453,454,455,456,457],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[459,460,461,462,463,464,390,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,115,491,492,493],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,2136,609,1534,{"spaceId":390,"name":390,"availableJournalPages":495,"announcement":499},[283,288,285,496,497,498],"volumes","about","community-reviewers",{"__typename":500,"sys":501,"preHeader":42,"title":503,"description":504,"image":505,"link":527},"Announcement",{"id":502},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[506],{"archive":387,"brandId":388,"copyright":28,"dateCreated":507,"dateModified":508,"datePublished":509,"description":28,"extension":510,"fileSize":512,"height":513,"id":514,"isPublic":387,"limited":387,"name":515,"orientation":403,"original":28,"thumbnails":516,"type":383,"watermarked":387,"width":523,"videoPreviewURLs":524,"tags":525,"textMetaproperties":526,"src":517},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[511],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":517,"thul":518,"mini":519,"WebsiteWebP_L":520,"WebsiteWebP_M":521,"Guidelines":522},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":528,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":531,"isPreviewPage":375,"hasSupplementalData":375,"showCrossmarkWidget":13,"articleTemplate":700,"currentArticlePageMetaInfo":701,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":532,"doi":533,"title":534,"acceptanceDate":535,"receptionDate":536,"publicationDate":537,"lastModifiedDate":538,"isPublished":13,"abstract":539,"researchTopic":540,"articleType":546,"stage":549,"keywords":551,"authors":557,"editors":625,"reviewers":635,"journal":655,"section":663,"impactMetrics":665,"volume":669,"articleVolume":670,"relatedArticles":671,"isPublishedV2":375,"contents":672,"files":675},900313,"10.3389/fcvm.2022.900313","Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China",["Date","2022-06-07T16:12:34.000Z"],["Date","2022-03-20T10:07:15.000Z"],["Date","2022-06-27T00:00:00.000Z"],["Date","2025-11-25T03:56:05.719Z"],"Background: Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited literature describing the variants responsible for ATTRv in areas outside the United State, the United Kingdom and Europe. This study was performed to describe the clinical characteristics and genotypic profiles of this disease in South China. Methods: This was a single-center retrospective study that evaluated 29 patients with a confirmed diagnosis of hereditary transthyretin amyloid cardiomyopathy enrolled from January 2016 to November 2021. Results: 93.1% patients were male and the median age of symptom onset was 53 (46, 62.5) years old. The initial manifestations of ATTR-CM were cardiovascular symptoms (55.2%), neuropathy (41.4%) and vitreous opacity (3.4%). Phenotypes at diagnosis were mixed (82.8%), predominant cardiac (6.9%), neurological (6.9%) and ophthalmic (3.4%). Poor R-wave progression (41%), pseudo-infarct (31%) and low-voltage (31%) patterns were common findings on electrocardiogram. Unexplained increased wall thickness was observed in all 29 patients, with mean septal and posterior wall thicknesses of 14.256.26 mm and 15.342.84 mm, respectively. Diastolic dysfunction was also seen in all 29 patients, and 17 (58%) had a restrictive fill pattern at diagnosis. Nine different missense mutations of the TTR gene were found in 29 patients from 23 families, with c.349GT (p.Ala117Ser) the most common mutation. The median survival time after diagnosis was 47.6 (95% CI 37.9-57.4) months, with 1, 3 and 5-year survival rates of 91.2%, 74% and 38% respectively. Patients with advanced heart failure (National Amyloidosis Staging stage II/III) had worse survival than stage I [Breslow (Generalized Wilcoxon), 2=4.693, P=0.03)]. Conclusions: ATTR amyloidosis genotypes and phenotypes are highly heterogeneous. Advanced heart failure predicts a poor prognosis. Understanding the  different clinical profiles of ATTR cardiac amyloidosis with different genotype is important to its early recognition.  ",{"id":541,"title":542,"articlesCount":543,"isMagazinePage":13,"slug":544,"isOpenForSubmission":375,"views":545},26330,"Novel Phenotyping and Risk Stratification Strategies for Heart Failure",16,"novel-phenotyping-and-risk-stratification-strategies-for-heart-failure",68708,{"id":547,"name":548},24,"Original Research",{"id":550,"name":19},18,[552,553,554,555,556],"hereditary","transthyretin amyloidosis","cardiomyopathy","prognosis","China",[558,566,572,578,584,590,596,602,608,613,619],{"id":559,"firstName":560,"middleName":19,"lastName":561,"givenNames":562,"isCorresponding":375,"isProfilePublic":13,"userId":559,"email":-1,"affiliations":563},1615373,"Shuai","Wang","Shuai ",[564],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},"Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University",{"id":387,"firstName":567,"middleName":19,"lastName":568,"givenNames":569,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":570},"Wenke","Peng","Wenke ",[571],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":573,"middleName":19,"lastName":574,"givenNames":575,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":576},"Min","Pang","Min ",[577],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":579,"middleName":19,"lastName":580,"givenNames":581,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":582},"Ling","Mao","Ling ",[583],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":585,"firstName":586,"middleName":19,"lastName":568,"givenNames":587,"isCorresponding":375,"isProfilePublic":13,"userId":585,"email":-1,"affiliations":588},1406875,"Daoquan","Daoquan ",[589],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":594},"Bilian","Yu","Bilian ",[595],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":597,"middleName":19,"lastName":598,"givenNames":599,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":600},"Sha","Wu","Sha ",[601],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":603,"middleName":19,"lastName":604,"givenNames":605,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":606},"Die","Hu","Die ",[607],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":609,"middleName":19,"lastName":609,"givenNames":610,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":611},"Yang","Yang ",[612],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":614,"middleName":19,"lastName":615,"givenNames":616,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":617},"Jia","He","Jia ",[618],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":620,"middleName":19,"lastName":621,"givenNames":622,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":623},"Mingqi","Ouyang","Mingqi ",[624],{"organizationName":565,"countryName":556,"cityName":19,"stateName":19,"zipCode":19},[626],{"id":627,"firstName":628,"middleName":19,"lastName":629,"givenNames":630,"isCorresponding":375,"isProfilePublic":13,"userId":627,"email":-1,"affiliations":631},1401135,"Jeffrey Shi Kai","Chan","Jeffrey Shi Kai ",[632],{"organizationName":633,"countryName":634,"cityName":19,"stateName":19,"zipCode":19},"Cardiovascular Analytics Group","Hong Kong, SAR China",[636,645],{"id":637,"firstName":638,"middleName":19,"lastName":639,"givenNames":640,"isCorresponding":375,"isProfilePublic":13,"userId":637,"email":-1,"affiliations":641},788222,"Concetta","Zito","Concetta ",[642],{"organizationName":643,"countryName":644,"cityName":19,"stateName":19,"zipCode":19},"University of Messina","Italy",{"id":646,"firstName":647,"middleName":648,"lastName":649,"givenNames":650,"isCorresponding":375,"isProfilePublic":13,"userId":646,"email":-1,"affiliations":651},820312,"Marcus","V","Pinto","Marcus  V",[652],{"organizationName":653,"countryName":654,"cityName":19,"stateName":19,"zipCode":19},"Mayo Clinic","United States",{"id":115,"slug":117,"name":116,"shortName":656,"electronicISSN":657,"field":658,"specialtyId":28,"journalSectionPaths":661},"Front. Cardiovasc. Med.","2297-055X",{"id":659,"domainId":660},103,2,[662],{"section":663},{"id":184,"name":185,"slug":186,"specialtyId":664},506,{"views":666,"downloads":667,"citations":668},4742,1407,13,9,"Volume 9 - 2022",[],{"titleHtml":534,"fullTextHtml":673,"menuHtml":674},"\u003Cdiv class=\"JournalAbstract\">\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\n\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\n\u003Ca href=\"https://loop.frontiersin.org/people/1615373\" class=\"user-id-1615373\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1615373/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\nShuai Wang\">Shuai Wang\u003C/a>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Wenke Peng\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Wenke Peng\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Min Pang\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Min Pang\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ling Mao\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ling Mao\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1406875\" class=\"user-id-1406875\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1406875/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Daoquan Peng&#xA;\">Daoquan Peng\u003C/a>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Bilian Yu\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Bilian Yu\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sha Wu\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sha Wu\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Die Hu\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Die Hu\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Yang Yang\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Yang Yang\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jia He\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jia He\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Mingqi Ouyang\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Mingqi Ouyang\u003C/span>\u003C/div>\n\u003Cul class=\"notes\">\u003Cli class=\"pl0\">Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha, China\u003C/li>\n\u003C/ul>\n\u003Cp class=\"mb15\">\u003Cstrong>Background:\u003C/strong> Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited literature describing the variants responsible for ATTRv in areas outside the United State, the United Kingdom and Europe. This study was performed to describe the clinical characteristics and genotypic profiles of this disease in South China.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cstrong>Methods:\u003C/strong> This was a single-center retrospective study that evaluated 29 patients with a confirmed diagnosis of hereditary transthyretin amyloid cardiomyopathy enrolled from January 2016 to November 2021.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cstrong>Results:\u003C/strong> 93.1% patients were male and the median age of symptom onset was 53 (46, 62.5) years old. The initial manifestations of ATTR-CM were cardiovascular symptoms (55.2%), neuropathy (41.4%) and vitreous opacity (3.4%). Phenotypes at diagnosis were mixed (82.8%), predominant cardiac (6.9%), neurological (6.9%) and ophthalmic (3.4%). Poor R-wave progression (41%), pseudo-infarct (31%) and low-voltage (31%) patterns were common findings on electrocardiogram. Unexplained increased wall thickness was observed in all 29 patients, with mean septal and posterior wall thicknesses of 14.25 &#x000B1; 6.26 mm and 15.34 &#x000B1; 2.84 mm, respectively. Diastolic dysfunction was also seen in all 29 patients, and 17 (58%) had a restrictive fill pattern at diagnosis. Nine different missense mutations of the TTR gene were found in 29 patients from 23 families, with c.349G&#x0003E;T (p.Ala117Ser) the most common mutation. The median survival time after diagnosis was 47.6 (95% CI 37.9-57.4) months, with 1, 3 and 5-year survival rates of 91.2%, 74% and 38% respectively. Patients with advanced heart failure (National Amyloidosis Staging stage II/III) had worse survival than stage I [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, \u003Ci>P\u003C/i> = 0.03)].\u003C/p>\n\u003Cp class=\"mb0\">\u003Cstrong>Conclusions:\u003C/strong> ATTR amyloidosis genotypes and phenotypes are highly heterogeneous. Advanced heart failure predicts a poor prognosis. Understanding the different clinical profiles of ATTR cardiac amyloidosis with different genotype is important to its early recognition.\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"JournalFullText\">\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\n\u003Ch2>Introduction\u003C/h2>\n\u003Cp class=\"mb15\">Hereditary transthyretin amyloidosis (ATTRv) represents a group of severe diseases with a broad spectrum of genotypes and phenotypes caused by transthyretin (TTR) gene mutations. ATTR is the result of dissociation of the transthyretin tetramer into monomers that mis-fold, forming amyloid deposits in the extracellular space (\u003Ca href=\"#B1\">1\u003C/a>). The most common manifestations of ATTR are polyneuropathy and cardiomyopathy (\u003Ca href=\"#B2\">2\u003C/a>). As our understanding of the molecular mechanisms behind ATTR amyloidosis improves, disease-modifying treatments including stabilizing molecular (tafamidis) and genetic silencers (partisiran and inotersen) have been made available. As pharmacotherapy is more effective in the early stages of the disease, the early diagnosis of ATTR by understanding its genotype-phenotype correlations is important (\u003Ca href=\"#B3\">3\u003C/a>&#x02013;\u003Ca href=\"#B5\">5\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">More than 120 mutations of the TTR gene have been described, and as of December 2021 there are 68 pathogenic/likely pathogenic variants of the TTR gene listed in the National Center for Biotechnology Information ClinVar database (\u003Ca href=\"#B6\">6\u003C/a>&#x02013;\u003Ca href=\"#B8\">8\u003C/a>). Some genotype-phenotype variability has been reported. Although the THAOS registry collected ATTR phenotypes and genotypes from continental Western Europe and the United States, few studies have been performed in China. Two recent retrospective cohort studies revealed that the mutation of TTR in Chinese patients may be quite different from that seen in the United States and Europe (\u003Ca href=\"#B9\">9\u003C/a>, \u003Ca href=\"#B10\">10\u003C/a>). Further, those two studies mainly discussed ATTRv patients from northern China and one study focused on ATTRv patients with neuropathy as main symptom. Here, we report the phenotype and genotype of 29 patients with ATTRv cardiomyopathy (ATTRv-CM) from 23 unrelated South Chinese families.\u003C/p>\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\n\u003Ch2>Methods\u003C/h2>\n\u003Ch3 class=\"pt0\">Study Design and Population\u003C/h3>\n\u003Cp class=\"mb0\">This was a descriptive, observational, and retrospective study that included patients diagnosed with hereditary ATTRv-CM at our institution from January 2016 to November 2021. The study was undertaken in accordance with the Declaration of Helsinki and was approved by the ethics committee of Second Xiangya Hospital. Due to the retrospective nature of this study, informed consent was waived for patients who had died. Otherwise, all patients provided written informed consent.\u003C/p>\n\u003Ch3>Diagnosis of Hereditary ATTR Cardiac Amyloidosis\u003C/h3>\n\u003Cp class=\"mb15\">The diagnosis of hereditary ATTRv-CM was established by clinical presentation, family history, echocardiography, tissue biopsy and DNA sequencing for the presence of a mutation in the TTR gene. Cardiac magnetic resonance (CMR) and \u003Csup>99m\u003C/sup>technetium (\u003Csup>99m\u003C/sup>Tc)-pyrophosphate (PYP) scintigraphy were performed in select cases. All included patients had a positive tissue biopsy (endocardium or extracardiac, e.g., abdominal adipose tissue or vitreous body) for amyloidosis and a pathogenic/likely pathogenic TTR variant. Light chain amyloidosis was ruled out by confirming a normal free light chain ratio and the absence of detectable serum and/or urine monoclonal protein. Patients without a related gene mutation on TTR gene sequencing were excluded.\u003C/p>\n\u003Cp class=\"mb15\">The date of symptom onset was reported by the patient as the date on which symptoms related to amyloidosis first were noted. The date of diagnosis was the date on which the diagnosis of amyloidosis was confirmed histologically.\u003C/p>\n\u003Cp class=\"mb15\">Phenotype categories based on clinical presentation at the time of diagnosis were: 1) predominantly cardiac. 2) predominantly neurological. 3) mixed (cardiac and neurological); and 4) ophthalmic. Patients with a predominantly cardiac phenotype were those (1) with heart failure, dyspnea and/or abnormal electrocardiogram findings caused by rhythm disturbance and (2) who did not have more than mild neurological or gastrointestinal symptoms (excluding erectile dysfunction, constipation and carpal tunnel syndrome). Patients with a predominantly neurologic phenotype were those with (1) walking disability of any severity, other neurologic symptoms of any severity or gastrointestinal symptoms (early satiety, nausea, vomiting, unintentional weight loss, diarrhea, constipation or fecal incontinence) of any severity and (2) who did not have heart failure, dyspnea, or an abnormal ECG due to a rhythm disturbance. Patients with a (3) mixed phenotype were patients who had at least 1 cardiac and neurological symptom as described above. Patients with (4) an ophthalmic phenotype had vitreous opacity with none of the cardiac or neurological symptoms described above.\u003C/p>\n\u003Cp class=\"mb15\">Cardiomyopathy was defined as an end-diastolic thickness of the left ventricular wall &#x0003E; 1.2 cm (in the absence of any other plausible causes of LV hypertrophy). Other clues suggestive of cardiac amyloidosis included granular sparkling appearance of the ventricular myocardium, increased thickness of the atrioventricular valves or the interatrial septum and reduced tissue doppler e&#x00027; velocities. CMR and \u003Csup>99m\u003C/sup>Tc-PYP were performed in select cases. Characteristic CMR findings of (1) the inability to suppress or &#x0201C;null&#x0201D; the myocardial signal or (2) the presence of diffuse subendocardial or transmural enhancement patterns on late gadolinium enhancement CMR were recorded. Grade 2 or 3 cardiac uptake on \u003Csup>99m\u003C/sup>Tc-PYP scintigraphy was also recorded.\u003C/p>\n\u003Cp class=\"mb0\">N-terminal pro-B type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), cardiac troponin (cTnT), modified poly neuropathy disability (PND) score and the U.K. National Amyloidosis Staging (NAC) and New York Heart Association (NYHA) stages were recorded. NAC Stage I is defined as NT-proBNP &#x02264; 3000 ng/L and eGFR &#x02265; 45 mL/min, and NAC stage III was defined as NT-proBNP&#x0003E; 3000 ng/L and eGFR &#x0003C; 45 mL/min. The remainder of the patients were assigned to NAC stage II.\u003C/p>\n\u003Ch3>Neurological Work-Up\u003C/h3>\n\u003Cp class=\"mb0\">Neurological examination included an assessment of motor, cerebellar and reflex function as well as screening for sensory function. Muscle strength was documented according to the Medical Research Council (MRC) scale (5/5 normal strength, 0/5 no contractions). Motor and sensory nerve conduction studies were performed on patients with reported neurologic symptoms. The PND score was used to stage patients with ATTRv and polyneuropathy at baseline. PND I was defined as sensory disturbances in the extremities but preserved walking capacity; PND II was defined as difficulty walking but without the need for a walking stick; PND III was defined as sticks or crutches required for walking; and PND IV was defined as confined to a wheelchair or bed.\u003C/p>\n\u003Ch3>Genetic Testing of the TTR Gene\u003C/h3>\n\u003Cp class=\"mb0\">Genomic DNA was isolated from whole peripheral blood using standard techniques. Exon 1&#x02013;4 of the \u003Ci>TTR\u003C/i> gene were amplified with polymerase chain reaction. Sequences of the \u003Ci>TTR\u003C/i> gene (NM_000371.3; NG_009490.1) were analyzed using the Applied BioSystems SeqScape software v4.0 (Carlsbad, USA) and the DNA Dynamo Sequence Analysis Software (North Wales, UK). The datasets presented in this study can be found in an online repository. The name of the repository and its accession numbers can be found in the supplementary material (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>). Genetic testing and clinical penetrance assessments were performed on family members for probands if available.\u003C/p>\n\u003Ch3>Follow-Up\u003C/h3>\n\u003Cp class=\"mb0\">Patient follow-ups at 6 to 12-month intervals included an ECG, NT-proBNP and yearly echocardiogram. Mutation carriers were surveilled via regular (yearly) telephone contact.\u003C/p>\n\u003Ch3>Statistical Analyses\u003C/h3>\n\u003Cp class=\"mb0\">Continuous variables are reported as mean &#x000B1; SD or median and interquartile range (IQR) (for non-normal distributions). Categorical variables are reported as percentages. Kaplan-Meier survival was calculated from the date of the original diagnosis to the date of death or the most recent contact. Gehan-Breslow-Wilcoxon method was used to compare survival curves. All tests were 2-tailed and a \u003Ci>P\u003C/i>-value &#x0003C; 0.05 was considered statistically significant. Statistical analyses were performed using SPSS Statistics (version 26. IBM Corp., Chicago, IL, USA).\u003C/p>\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\n\u003Ch2>Results\u003C/h2>\n\u003Ch3 class=\"pt0\">Clinical Characteristics of Patients With ATTR Cardiac Amyloidosis\u003C/h3>\n\u003Cp class=\"mb0\">The clinical characteristics at diagnosis of the 29 patients are summarized in \u003Ca href=\"#T1\">Tables 1\u003C/a>, \u003Ca href=\"#T2\">2\u003C/a>. Twenty-seven (93.1%) patients were male. The median age at symptom onset was 53 (46, 62.5) years and the median age at diagnosis was 56 (47.75&#x02013;66.25) years. The median time from symptom onset to diagnosis was 24 (12&#x02212;24) months and the median course from diagnosis to the last visit was 15 (6.5&#x02013;37.5) months.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" name=\"Table1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 1\u003C/strong>. Clinical Manifestations of ATTRv-CM and the \u003Ci>TTR\u003C/i> variant Ala97Ser.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" name=\"Table2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 2\u003C/strong>. Complementary baseline tests for ATTRv&#x02013;CM and the \u003Ci>TTR\u003C/i> variant Aal97Ser.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">Dyspnea on exertion and limited physical capacity were the initial complaints that prompted a comprehensive cardiological examination in 16 cases (55.2%). Another 12 (41.4%) patients presented with distal sensory disturbances and/or weakness predominantly of the lower limbs. One patient reported vitreous opacity as their initial manifestation and had asymptomatic cardiac hypertrophy at diagnosis.\u003C/p>\n\u003Cp class=\"mb15\">Twenty-four (82.8%) patients presented with a mixed phenotype that included both cardiomyopathy and neuropathy, while 2 (6.9%) had a predominantly cardiac phenotype and 2 (6.9%) had a predominantly neurological phenotype. One patient (3.4%) presented with vitreous opacity with asymptomatic myocardial hypertrophy. Peripheral and autonomic nerve dysfunction were found in 25 (86.2%) and 14 (48.3%) subjects at diagnosis, respectively. Six patients (20.7%) had a history of uni- or bilateral carpal tunnel syndrome. Lumber spinal stenosis was reported in one patient. The PND score was used to describe the severity of the peripheral neuropathy (\u003Ca href=\"#T1\">Table 1\u003C/a>). At diagnosis, 72.4% (21) had severe heart failure (NYHA III/IV), 3.4% (1) had mild heart failure (NYHA II) and 24.1% (7) had asymptomatic myocardial hypertrophy (\u003Ca href=\"#T1\">Table 1\u003C/a>). Elevated NT-proBNP and cTnT were found in 29 (100%) and 28 (97%) patients, respectively. The median NT-proBNP and cTnT levels were 2789 (1206&#x02013;5024) pg/ml and 61.5 (42.8&#x02013;88.9) pg/ml at diagnosis. Only one patient had an eGFR &#x0003C;45 and the median eGFR was 81.7 (66.4&#x02013;93.6) ml/min/1.73 m\u003Csup>2\u003C/sup> (\u003Ca href=\"#T2\">Table 2\u003C/a>). Of the 29 patients, 19 (65.6%) were NAC stage I, 9 (31%) stage II and 1 (3.4%) stage III.\u003C/p>\n\u003Cp class=\"mb15\">Electrocardiogram abnormalities were evident in 15 (51.7%) patients at diagnosis. Two (6.9%) had atrial fibrillation, 5 (17.2%) presented with an atrial-ventricular block and 2 went on to require a permanent pacemaker. The classic low-voltage pattern of ATTR-CM was found in 9 (31%) patients, while a low-voltage pattern according to the Sokolow criteria was found in 8 (27.5%). A pseudo-infarct pattern was found in 9 (31%) patients and poor R wave progression was found in 12 (41%, \u003Ca href=\"#T2\">Table 2\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">Unexplained increased wall thickness (&#x0003E;12 mm) and diastolic dysfunction were observed in 29 (100%) patients. Two (6.9%) had systolic dysfunction with an ejection fraction &#x0003C;50%. Restrictive filling (e&#x00027; &#x0003C;5 cm/s) was present in 17 (58%) patients at diagnosis. Pericardial effusions were present in 9 patients (31%). The mean septal and posterior wall thicknesses of the cohort were 16.39&#x000B1;3.04 mm and 15.34&#x000B1;2.84 mm, respectively, and the mean systolic left atrial diameter was 39.47&#x000B1;5.54 mm. The mean LVEF was 52.65&#x000B1;10.6%. CMR was performed on 16 (55.2%) patients to diagnose ATTR cardiac amyloidosis, all of which showed diffuse subendocardial or transmural LGE and abnormal gadolinium kinetics. \u003Csup>99m\u003C/sup>TC-PYP scintigraphy was performed on 9 patients (31%). Seven had grade 3 cardiac uptake and 2 patients had grade 2 uptake. Biopsies were performed on all patients, and originated from the abdominal fat (28), endomyocardium (1) or vitreous body (1) (\u003Ca href=\"#T2\">Table 2\u003C/a>). All samples were positive on Congo red staining and TTR immunochemistry. Four patients (9.5%) in this cohort were on tafamidis post-enrollment, and no patient received a liver transplant.\u003C/p>\n\u003Ch3>Genetic Spectrum of TTR Mutations\u003C/h3>\n\u003Cp class=\"mb0\">Genetic testing of the probands and their family members identified 9 different missense \u003Ci>TTR\u003C/i> mutations [Asp18Asn(p.Asp38Asn), Ser23Asn(p.Ser43Asn), Glu42Gly (p.Glu62Gly), Gly47Glu(p.Gly67Glu), Leu55Arg(p.Leu75Arg), Thr59Lys(p.Thr79Lys), Glu61Lys(p.Glu81Lys), His108Arg (p.His108Arg), Ala97Ser(p.Ala117Ser)] and 1 small deletion mutation (3&#x00027;UTR c.624_632 del GACTTCTCC) in 29 patients from 23 families. Pedigree analysis found another 11 asymptomatic mutation carriers without electrocardiographic and echocardiographic abnormalities. The predominant genotypes identified in ATTR-CA were the Ala97Ser (p.Ala117Ser) mutation (11/29, 37.9%) followed by Thr59Lys (p.Thr79Lys) (5, 17.2%) (\u003Ca href=\"#F1\">Figure 1\u003C/a>). Of these variants, Asp18Asn, Ser23Asn, Glu42Gly, Gly47Glu, Thr59Lys, Glu61Lys, His88Arg and Ala97Ser were associated with the mixed phenotype while Leu55Arg was associated with the ophthalmic phenotype. The deletion mutation was found in a patient with a cardiac phenotype (\u003Ca href=\"#T3\">Table 3\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" name=\"figure1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 1\u003C/strong>. Distribution of \u003Ci>TTR\u003C/i> mutations in a cohort of ATTR-CA patients from South China.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 3\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" name=\"Table3\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 3\u003C/strong>. Genotype distribution in probands and family members.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0 w100pc float_left mt15\">Ala97Ser was the most common mutation in this cohort. 72.7% (8/11 cases) of patients carrying the Ala97Ser presented with evidence of heart failure at confirmed diagnosis of ATTRv cardiac amyloidosis, with 63.7% (7/11) having NYHAIII/IV (\u003Ca href=\"#T1\">Table 1\u003C/a>). All patients with Ala97Ser mutations initially presented with neurological dysfunction, but cardiac symptoms followed 2&#x02013;9 years later. The median age of onset of neurological symptom related to ATTR amyloidosis in patients carrying the Ala97Ser variant was 65 (62&#x02013;67) years old and the median time from neurological symptom onset to diagnosis of ATTRv-CM was 48 (24&#x02013;102) months.\u003C/p>\n\u003Ch3>Survival\u003C/h3>\n\u003Cp class=\"mb0\">During January 2016 to November 2021, 29 patients were diagnosed with hereditary ATTRv-CM and followed up at our institution. The date when symptoms related to ATTRv began, (which was 30 (12, 54) months before diagnosis of ATTR-CM), was recorded according to the patient&#x00027;s report. The mortality rate of the cohort over a median follow-up of 14 (5.75, 32.25) months was 7/29 (24%). The estimated median survival times after initial symptom onset related to ATTRv and at confirmed diagnosis of ATTRv-CM by Kaplan-Meier survival curve analysis were 131 (95%CI 88.6&#x02013;173.7) and 47.6 (95%CI 37.9&#x02013;57.4) months, respectively. According to Kaplan-Meier survival curve analysis, the estimated 3-, 5- and 10-year survival rates after symptom onset were 90%, 70% and 52.6%, respectively (\u003Ca href=\"#F2\">Figure 2A\u003C/a>). The overall 1-year survival rate after diagnosis was 91.2%, and the 3- and 5-year survival rates were 74% and 38%, respectively (\u003Ca href=\"#F2\">Figure 2B\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" name=\"figure2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 2. (A)\u003C/strong> Kaplan-Meier survival curves of data obtained from ATTR-CA symptom onset. Overall survival at 12-, 36-, 60-, and 120- months after symptom onset were 100%, 90%, 70% and 52.6%, respectively. Numbers below the plot represent the number of subjects at risk at each time point. Cumulative events refer to all-cause death. The median survival time after symptom onset was 131 (95%CI 88.6&#x02013;173.7) months. \u003Cstrong>(B)\u003C/strong> Kaplan-Meier survival curves at confirmed diagnosis. Overall survival at 12-, 36-, and 60- months was 91.2%, 74%, and 38% respectively. Numbers below the plot represent the number of subjects at risk at each time point. Cumulative events refer to all-cause death. The estimated median survival time after confirmed diagnosis of ATTRv-CM was 47.6 (95%CI 37.9&#x02013;57.4) months.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mt15 w100pc float_left\">For patient carrying Ala97Ser variant, survival curve analysis revealed the estimated mean survival time after symptom onset and at diagnosis were 181(95%CI 120.2, 241.8) months and 38.5 (95%CI 30.9, 46.1) months. Patient with other variants had estimated mean survival time of 102 (95%CI 73.1, 132.1) months after symptom onset and 43.9 (95%CI 31.3, 56.4) months at diagnosis. Cumulative survival rate at 150 months after symptom onset was 66.7% in Ala97Ser and 0% in other variants. The difference in survival curve for Ala97Ser and other variants at symptom onset was not significant [Breslow (Generalized Wilcoxon), &#x003C7;2 = 2.92, \u003Ci>p\u003C/i> = 0.087] (\u003Ca href=\"#F3\">Figure 3A\u003C/a>). No significant difference was found in survival curve between patient carrying Ala97Ser and other variants at confirmed diagnosis. [Breslow (Generalized Wilcoxon), &#x003C7;2 = 0.859, \u003Ci>p\u003C/i> = 0.35] (\u003Ca href=\"#F3\">Figure 3B\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" name=\"figure3\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 3. (A)\u003C/strong> Comparison of Kaplan-Meier survival curves of data obtained from ATTR-CA symptom onset between patients with Ala97Ser and other variants. There was no significant difference in survival in patients with Ala97Ser and other variants [Breslow (Generalized Wilcoxon), &#x003C7;2 = 2.92, \u003Ci>p\u003C/i> = 0.087]. \u003Cstrong>(B)\u003C/strong> Comparison of Kaplan-Meier survival curves at confirmed diagnosis between patients with Ala97Ser and other variants. Survival after diagnosis was not significantly different in patients with Ala97Ser and other variants [Breslow (Generalized Wilcoxon), &#x003C7;2 = 0.859, \u003Ci>p\u003C/i> = 0.35]. \u003Cstrong>(C)\u003C/strong> Kaplan-Meier survival curve for patients grouped by NAC stage at diagnosis. Patients with NAC stage II/III disease had worse survival than those with NAC stage I disease [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, \u003Ci>p\u003C/i> = 0.03)]. The median survival time of patients in NAT stage I was 48 months (95%CI 39&#x02013;63) and the cumulative survival at 60 months was 46.7%. The median survival time of patients in NAC stage II/III was 33 months (95%CI 13.7&#x02013;55.3) and the cumulative survival at 60 months was 0%.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0 w100pc float_left mt15\">Patient at an early disease stage (NAC stage I) tended to have a lower mortality rate, with a median survival time of 48 months (95%CI 39&#x02013;63 month) and a cumulative survival rate at 60 months of 46.7% [Breslow (Generalized Wilcoxon), &#x003C7;2 = 4.693, \u003Ci>p\u003C/i> = 0.03]. In contrast, the median survival time of patients at a later disease stage (NAC II, III) was 33 months (95%CI 13.7&#x02013;55.3), with a cumulative survival rate at 60 months of 0% (\u003Ca href=\"#F3\">Figure 3C\u003C/a>) All deaths were observed in patients with NYHA III-IV heart failure.\u003C/p>\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\n\u003Ch2>Discussion\u003C/h2>\n\u003Cp class=\"mb15\">Male predominance (93%) was observed in this cohort, which was higher than previous reports on ATTRv-CM whose samples were approximately 70% (\u003Ca href=\"#B11\">11\u003C/a>&#x02013;\u003Ca href=\"#B13\">13\u003C/a>). This may be due to the small sample size of this study. The underlying mechanism for male predominance is unclear. The small sample size of women did not permit summarization of the sex-related clinical characteristics of ATTRv-CM. However, a recent systematic literature review on sex-related differences in transthyretin amyloid cardiomyopathy revealed that women tended to have lower interventricular septal and posterior wall thicknesses, smaller left ventricular end diastolic diameters and a higher LV ejection fraction. It was postulated that the disparity in the incidence of ATTRv-CM between sexes may be due to either the cardioprotective effects of estrogen or sex-related differences in clinical presentation or disease characteristics (\u003Ca href=\"#B11\">11\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">A mixed phenotype was most common presentation in this cohort (82.8%), while a predominantly cardiac phenotype and neurological phenotype was seen in 6.9% of patients each. ATTRv phenotype is associated with \u003Ci>TTR\u003C/i> mutations. While some mutations are associated with a predominantly cardiac phenotype, others are primarily related to a neurological phenotype. Previously reported common cardiac mutations (Val122Ile, leu111Met, Thr60Alr, Ile68Leu) in ATTRv were not identified in our cohort (\u003Ca href=\"#B14\">14\u003C/a>). However, we found that non-cardiac mutations such as Asp18Asn, Ser23Asn, Glu42Gly, Gly47Glu, Thr59Lys, Glu61Lys, His88Arg and Ala97Ser were associated with a cardiac phenotype with or without neurologic symptoms. These differences in genotype-phenotype relationship may be the result of their diagnosis at different disease stages.\u003C/p>\n\u003Cp class=\"mb0\">Ten different \u003Ci>TTR\u003C/i> gene mutations, including 9 missense variants and 1 small deletion mutation, were identified. All of the missense variants have been listed as pathogenic or likely pathogenic in the TTR mutation and ClinVar databases (\u003Ca href=\"#T4\">Table 4\u003C/a>) (\u003Ca href=\"#B15\">15\u003C/a>&#x02013;\u003Ca href=\"#B23\">23\u003C/a>). The missense mutations were related to the mixed phenotype. Glu61Lys, which was previously found to cause ATTR neuropathy, had never been reported in ATTR-CM. The cardiac mutations Asp18Asn and His68Arg also caused neuropathy in our study. The small deletion \u003Ci>TTR\u003C/i> mutation (c.624_632delGACTTCTCC) was located outside the coding region in exon 3 of the \u003Ci>TTR\u003C/i> gene. As the patient&#x00027;s family history could not be collected due to the limited medical records of the deceased parents, it could not be excluded that this variant of unknown significance occurred by chance in a patient with wild-type ATTR.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 4\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" name=\"Table4\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-t004.jpg\" alt=\"www.frontiersin.org\" id=\"T4\" loading=\"lazy\">\n  \u003C/picture>\n\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 4\u003C/strong>. Bioinformatic results of the identified missense \u003Ci>TTR\u003C/i> mutations.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">In this study, 10 different mutations (\u003Ci>n\u003C/i> = 40) have been identified in probands and family members, with the most common being Ala97Ser (\u003Ci>n\u003C/i> = 16; 40%). In addition, Ala97Ser is the most common mutation in symptomatic patient (\u003Ci>n\u003C/i> = 11;37.9%). This was different in the United States, where Val1122Ile (p.Val142Ile) and Thr60Ala (p.T80A) were the most common mutations (\u003Ca href=\"#B14\">14\u003C/a>). In European countries, Val30Met was the most frequent mutation in subjects with ATTR in the THAOS registry, followed by Ile68Leu (\u003Ca href=\"#B12\">12\u003C/a>). This discrepancy may reflect the heterogeneity of ATTR genotypes between different countries. Ala97Ser has been previously found to be a common ATTR mutation in cohorts of Chinese patients with predominant neurologic phenotypes, including patients from north China and Taiwan. It has also been reported in Chinese Malaysians (\u003Ca href=\"#B10\">10\u003C/a>, \u003Ca href=\"#B24\">24\u003C/a>&#x02013;\u003Ca href=\"#B27\">27\u003C/a>). (\u003Ca href=\"#SM2\">Supplementary Table 2\u003C/a>) Similar with previous studies, male predominance was observed in Ala97Ser. Consistant with other studies, our study found that all patients with Ala97Ser initially presented with a predominantly neurologic phenotype in the early stages of disease. However, the proportion of patients developing cardiomyopathy as the disease progressed was higher (72.7%) than previous reports. Most Ala97Ser patients exhibited a mixed phenotype at their time of diagnosis in our study, which suggests that diagnosis was delayed until a late disease stage. This may be attributed to the difficulty with diagnosing ATTR in patients with isolated peripheral neuropathy symptoms, especially when reg flag symptoms such as carpal tunnel syndrome and lumber stenosis were rarely presented in this cohort. In this situation, family history and genetic examination were important to the early diagnosis of an ATTR patient with a neurological phenotype. On the other hand, CMR and \u003Csup>99m\u003C/sup>Tc-PYP scintigraphy may help to identify myocardial involvement in patients who does not report symptom of heart failure due to limited physical activity caused by neuropathy.\u003C/p>\n\u003Cp class=\"mb15\">Survival is poor in patients with ATTR cardiac amyloidosis. Although survival varies by genotype, phenotype, and disease stage, most series have reported a median survival of 2.5&#x02013;3.5 years for patients with heart failure (\u003Ca href=\"#B8\">8\u003C/a>). There was a poorer prognosis in the present work for subjects with more severe heart failure, with a 5 year survival rate of &#x0003C;20% for those with NYHA III-IV disease. Several studies have noted the prognostic role of NT-proBNP (\u003Ca href=\"#B28\">28\u003C/a>). The NAC staging system includes NT-proBNP and eGFR and has a good prognostic accuracy (\u003Ca href=\"#B29\">29\u003C/a>). Patients with advanced NAC stage (stage 2, 3) had a poor prognosis (median survival: 34.5 months, 3-year survival rate: 43%). More advanced NYHA classification at diagnosis also tended to predict a poor prognosis, although there was no statistical significance due to the limited sample size of our study. Phenotype, genotype, initial manifestation and severity of peripheral neuropathy as shown by PND score were not predictive in our study.\u003C/p>\n\u003Cp class=\"mb15\">The natural average life expectancy is 9 to 13 years after the symptom onset and death usually results from cardiac involvement and cachexia (\u003Ca href=\"#B30\">30\u003C/a>). As disease modifying therapy, liver transplantation has been demonstrated to prolong survival. However, the statistics are mostly related to patients with ATTR V30M (\u003Ca href=\"#B31\">31\u003C/a>), which was not identified in our study cohort. Different from previous two cohort studies in China, no patient received liver transplantation in our cohort because the following reasons 1) For patients with advanced heart failure, liver transplantation does not provide a complete cure for the disease due to the newly formed amyloid around the preexisting amyloid seeds (\u003Ca href=\"#B32\">32\u003C/a>). Combining liver and heart transplantation may be a better strategy. 2) Liver transplantation is restricted by the availability of transplant organs as well as the advanced age and comorbidities of ATTR-CM patients. 3) The need for life-long immunosuppression therapy.\u003C/p>\n\u003Cp class=\"mb15\">Tafamidis, a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by China Food and Drug Administration for the treatment of inherited or wild type cardiac transthyretin amyloidosis in adult patients in 2020. However, only a few patients could afford this disease modifying therapy because the price of tafamidis was expensive (64,100\u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_n/fcvm-09-900313-i001.gif\" style=\"float:none;margin:0\" alt=\"yes\" >/month in 2020, then reduced to 24,650\u003Cimg src=\"https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_n/fcvm-09-900313-i001.gif\" style=\"float:none;margin:0\" alt=\"yes\" >/month in 2021). Up to November 2021, only 9.5% (\u003Ca href=\"#B4\">4\u003C/a>) patients received tafamidis in our cohort. Fortunately, more patients will have chance to receive this disease modifying therapy since National Health Insurance Administration has issued a national coverage decision to incorporate Tafamidis into medical insurance payouts in 2022.\u003C/p>\n\u003Cp class=\"mb0\">There are several limitations to our study. First, this was a retrospective study that included a limited sample size. Second, all probands were admitted to our cardiology department first, which results in selection bias that may not permit the description of the actual phenotype-genotype relationship. Third, nuclear scintigraphy was only used in 9 (31%) patients. Expanding the sample size and long-term follow-up of the proband patients and their genotype positive phenotype negative pedigree is needed to understand the relationship between ATTRv genotype and disease course.\u003C/p>\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\n\u003Ch2>Conclusion\u003C/h2>\n\u003Cp class=\"mb0\">Hereditary ATTRv-CM has heterogeneous phenotypes and genotypes. Most patients had a mixed phenotype that included both cardiomyopathy and neuropathy. Ala97Ser, the most common mutation in South China, initially presented as peripheral and automatic neuropathy and progressed to heart failure at a later disease stage. The prognosis of ATTR was poor, and patients with NYHA III-IV and NAC stage 3 had the worst prognosis.\u003C/p>\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\n\u003Ch2>Data Availability Statement\u003C/h2>\n\u003Cp class=\"mb0\">The original contributions presented in the study are included in the article/\u003Ca href=\"#h14\">Supplementary Materials\u003C/a>, further inquiries can be directed to the corresponding author.\u003C/p>\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\n\u003Ch2>Ethics Statement\u003C/h2>\n\u003Cp class=\"mb0\">The studies involving human participants were reviewed and approved by the Ethics Committee of Second Xiangya Hospital. The patients/participants provided their written informed consent to participate in this study.\u003C/p>\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\n\u003Ch2>Author Contributions\u003C/h2>\n\u003Cp class=\"mb0\">SW wrote the protocol, evaluated cardiac involvement, analyzed the results and wrote the manuscript. WP and MP collected the data. LM did the TTR sequencing and analyzed the gene data. DP conceived of the study. BY revised the manuscript and provided guidance for the study. SW, BY, DP, SW, DH, YY, and JH evaluated the patients and made the clinical diagnosis for each patient. All authors contributed to the article and approved the submitted version.\u003C/p>\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\n\u003Ch2>Funding\u003C/h2>\n\u003Cp class=\"mb0\">This work was supported by grants from the National Nature Science Foundation Youth Project (81600359) and the National Nature Science Foundation General Project (81870336).\u003C/p>\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\n\u003Ch2>Conflict of Interest\u003C/h2>\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\n\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\n\u003Ch2>Publisher&#x00027;s Note\u003C/h2>\n\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\n\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\n\u003Ch2>Acknowledgments\u003C/h2>\n\u003Cp class=\"mb0\">We would like to thank all of the participating families and investigators for their important contributions to this study. Additional investigators contributing to analysis Na Liu.\u003C/p>\n\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\n\u003Ch2>Supplementary Material\u003C/h2>\n\u003Cp class=\"mb0\" id=\"SM1\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fcvm.2022.900313/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fcvm.2022.900313/full#supplementary-material\u003C/a>\u003C/p>\n\u003Ca id=\"h15\" name=\"h15\">\u003C/a>\n\u003Ch2>References\u003C/h2>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. \u003Ci>Lancet.\u003C/i> (2016) 387:2641&#x02013;54. doi: 10.1016/S0140-6736(15)01274-X\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26719234\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S0140-6736(15)01274-X\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AD+Wechalekar&#x00026;author=JD+Gillmore&#x00026;author=PN+Hawkins+&#x00026;publication_year=2016&#x00026;title=Systemic+amyloidosis&#x00026;journal=Lancet.&#x00026;volume=387&#x00026;pages=2641-54\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. \u003Ci>Cardiol Ther.\u003C/i> (2021) 10:289&#x02013;311. doi: 10.1007/s40119-021-00222-w\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34089151\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s40119-021-00222-w\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Koike&#x00026;author=T+Okumura&#x00026;author=T+Murohara&#x00026;author=M+Katsuno+&#x00026;publication_year=2021&#x00026;title=Multidisciplinary+approaches+for+transthyretin+amyloidosis&#x00026;journal=Cardiol+Ther.&#x00026;volume=10&#x00026;pages=289-311\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:1007&#x02013;16. doi: 10.1056/NEJMoa1805689\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34788394\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1805689\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MS+Maurer&#x00026;author=JH+Schwartz&#x00026;author=B+Gundapaneni&#x00026;author=PM+Elliott&#x00026;author=G+Merlini&#x00026;author=M+Waddington-Cruz+&#x00026;publication_year=2018&#x00026;title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=1007-16\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:22&#x02013;31. doi: 10.1056/NEJMoa1716793\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32286934\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1716793\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MD+Benson&#x00026;author=M+Waddington-Cruz&#x00026;author=JL+Berk&#x00026;author=M+Polydefkis&#x00026;author=PJ+Dyck&#x00026;author=AK+Wang+&#x00026;publication_year=2018&#x00026;title=Inotersen+treatment+for+patients+with+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=22-31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Adams D, Gonzalez-Duarte A, O&#x00027;Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:11&#x02013;21. doi: 10.1056/NEJMoa1716153\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29972753\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1716153\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Adams&#x00026;author=A+Gonzalez-Duarte&#x00026;author=WD+O&#x00027;Riordan&#x00026;author=CC+Yang&#x00026;author=M+Ueda&#x00026;author=AV+Kristen+&#x00026;publication_year=2018&#x00026;title=Patisiran,+an+RNAi+therapeutic,+for+hereditary+transthyretin+amyloidosis&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=11-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. \u003Ci>Nucleic Acids Res.\u003C/i> (2018) 46:D1062&#x02013;D7. doi: 10.1093/nar/gkx1153\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29165669\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkx1153\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Landrum&#x00026;author=JM+Lee&#x00026;author=M+Benson&#x00026;author=GR+Brown&#x00026;author=C+Chao&#x00026;author=S+Chitipiralla+&#x00026;publication_year=2018&#x00026;title=ClinVar%3A+improving+access+to+variant+interpretations+and+supporting+evidence&#x00026;journal=Nucleic+Acids+Res.&#x00026;volume=46&#x00026;pages=D1062-D7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Carry BJ, Young K, Fielden S, Kelly MA, Sturm AC, Avila JD, et al. Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records. \u003Ci>JACC CardioOncol.\u003C/i> (2021) 3:550&#x02013;61. doi: 10.1016/j.jaccao.2021.07.002\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34746851\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jaccao.2021.07.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BJ+Carry&#x00026;author=K+Young&#x00026;author=S+Fielden&#x00026;author=MA+Kelly&#x00026;author=AC+Sturm&#x00026;author=JD+Avila+&#x00026;publication_year=2021&#x00026;title=Genomic+screening+for+pathogenic+transthyretin+variants+finds+evidence+of+underdiagnosed+amyloid+cardiomyopathy+from+health+records&#x00026;journal=JACC+CardioOncol.&#x00026;volume=3&#x00026;pages=550-61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. \u003Ci>Circulation.\u003C/i> (2012) 126:1286&#x02013;300. doi: 10.1161/CIRCULATIONAHA.111.078915\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22949539\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1161/CIRCULATIONAHA.111.078915\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FL+Ruberg&#x00026;author=JL+Berk+&#x00026;publication_year=2012&#x00026;title=Transthyretin+(TTR)+cardiac+amyloidosis&#x00026;journal=Circulation.&#x00026;volume=126&#x00026;pages=1286-300\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. He S, Tian Z, Guan H, Li J, Fang Q, Zhang S. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. \u003Ci>Orphanet J Rare Dis.\u003C/i> (2019) 14:251. doi: 10.1186/s13023-019-1235-x\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31718691\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13023-019-1235-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+He&#x00026;author=Z+Tian&#x00026;author=H+Guan&#x00026;author=J+Li&#x00026;author=Q+Fang&#x00026;author=S+Zhang+&#x00026;publication_year=2019&#x00026;title=Clinical+characteristics+and+prognosis+of+Chinese+patients+with+hereditary+transthyretin+amyloid+cardiomyopathy&#x00026;journal=Orphanet+J+Rare+Dis.&#x00026;volume=14&#x00026;pages=251\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Du K, Li F, Wang H, Miao Y, Lv H, Zhang W, et al. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. \u003Ci>Ann Clin Transl Neurol.\u003C/i> (2021) 8:831&#x02013;41. doi: 10.1002/acn3.51328\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33739616\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/acn3.51328\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Du&#x00026;author=F+Li&#x00026;author=H+Wang&#x00026;author=Y+Miao&#x00026;author=H+Lv&#x00026;author=W+Zhang+&#x00026;publication_year=2021&#x00026;title=Hereditary+transthyretin+amyloidosis+in+mainland+China%3A+a+unicentric+retrospective+study&#x00026;journal=Ann+Clin+Transl+Neurol.&#x00026;volume=8&#x00026;pages=831-41\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Bruno M, Castano A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. \u003Ci>Heart Fail Rev.\u003C/i> (2021) 26:35&#x02013;45. doi: 10.1007/s10741-020-10010-8\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32794090\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10741-020-10010-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Bruno&#x00026;author=A+Castano&#x00026;author=A+Burton&#x00026;author=JL+Grodin+&#x00026;publication_year=2021&#x00026;title=Transthyretin+amyloid+cardiomyopathy+in+women%3A+frequency,+characteristics,+and+diagnostic+challenges&#x00026;journal=Heart+Fail+Rev.&#x00026;volume=26&#x00026;pages=35-45\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Damy T, Kristen AV, Suhr OB, Maurer MS, Plante-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). \u003Ci>Eur Heart J.\u003C/i> (2019). doi: 10.1093/eurheartj/ehz173\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30938420\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehz173\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Damy&#x00026;author=AV+Kristen&#x00026;author=OB+Suhr&#x00026;author=MS+Maurer&#x00026;author=V+Plante-Bordeneuve&#x00026;author=CR+Yu+&#x00026;publication_year=2019&#x00026;title=Transthyretin+cardiac+amyloidosis+in+continental+western+Europe%3A+an+insight+through+the+Transthyretin+Amyloidosis+Outcomes+Survey+(THAOS)&#x00026;journal=Eur+Heart+J.\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Batra J, Rosenblum H, Defilippis EM, Griffin JM, Saith SE, Gamino D, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to val122ile mutation: insights from noninvasive pressure-volume analysis. \u003Ci>J Card Fail.\u003C/i> (2021) 27:67&#x02013;74. doi: 10.1016/j.cardfail.2020.08.007\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32829019\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cardfail.2020.08.007\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Batra&#x00026;author=H+Rosenblum&#x00026;author=EM+Defilippis&#x00026;author=JM+Griffin&#x00026;author=SE+Saith&#x00026;author=D+Gamino+&#x00026;publication_year=2021&#x00026;title=Sex+differences+in+the+phenotype+of+transthyretin+cardiac+amyloidosis+due+to+val122ile+mutation%3A+insights+from+noninvasive+pressure-volume+analysis&#x00026;journal=J+Card+Fail.&#x00026;volume=27&#x00026;pages=67-74\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. \u003Ci>J Am Coll Cardiol.\u003C/i> (2019) 73:2872&#x02013;91. doi: 10.1016/j.jacc.2019.04.003\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31171094\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2019.04.003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FL+Ruberg&#x00026;author=M+Grogan&#x00026;author=M+Hanna&#x00026;author=JW+Kelly&#x00026;author=MS+Maurer+&#x00026;publication_year=2019&#x00026;title=Transthyretin+amyloid+cardiomyopathy%3A+JACC+state-of-the-art+review&#x00026;journal=J+Am+Coll+Cardiol.&#x00026;volume=73&#x00026;pages=2872-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. \u003Ci>Amyloid.\u003C/i> (2003) 10:160&#x02013;84. doi: 10.3109/13506120308998998\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14640030\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/13506120308998998\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LH+Connors&#x00026;author=A+Lim&#x00026;author=T+Prokaeva&#x00026;author=VA+Roskens&#x00026;author=CE+Costello+&#x00026;publication_year=2003&#x00026;title=Tabulation+of+human+transthyretin+(TTR)+variants,+2003&#x00026;journal=Amyloid.&#x00026;volume=10&#x00026;pages=160-84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Connors LH, Theberge R, Skare J, Costello CE, Falk RH, Skinner M, et al. New transthyretin variant (Ser23Asn) associated with familial amyloidosis in a Portuguese patient. \u003Ci>Amyloid.\u003C/i> (1999) 6:114&#x02013;8. doi: 10.3109/13506129909007311\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10439117\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/13506129909007311\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LH+Connors&#x00026;author=R+Theberge&#x00026;author=J+Skare&#x00026;author=CE+Costello&#x00026;author=RH+Falk&#x00026;author=M+Skinner+&#x00026;publication_year=1999&#x00026;title=New+transthyretin+variant+(Ser23Asn)+associated+with+familial+amyloidosis+in+a+Portuguese+patient&#x00026;journal=Amyloid.&#x00026;volume=6&#x00026;pages=114-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Ueno S, Uemichi T, Takahashi N, Soga F, Yorifuji S, Tarui S. Two novel variants of transthyretin identified in Japanese cases with familial amyloidotic polyneuropathy: transthyretin (Glu42 to Gly) and transthyretin (Ser50 to Arg). \u003Ci>Biochem Biophys Res Commun.\u003C/i> (1990) 169:1117&#x02013;21. doi: 10.1016/0006-291X(90)92011-N\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2363717\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/0006-291X(90)92011-N\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Ueno&#x00026;author=T+Uemichi&#x00026;author=N+Takahashi&#x00026;author=F+Soga&#x00026;author=S+Yorifuji&#x00026;author=S+Tarui+&#x00026;publication_year=1990&#x00026;title=Two+novel+variants+of+transthyretin+identified+in+Japanese+cases+with+familial+amyloidotic+polyneuropathy%3A+transthyretin+(Glu42+to+Gly)+and+transthyretin+(Ser50+to+Arg)&#x00026;journal=Biochem+Biophys+Res+Commun.&#x00026;volume=169&#x00026;pages=1117-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Pelo E, Da Prato L, Ciaccheri M, Castelli G, Gori F, Pizzi A, et al. Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred. \u003Ci>Amyloid.\u003C/i> (2002) 9:35&#x02013;41. doi: 10.3109/13506120209072443\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12000196\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/13506120209072443\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Pelo&#x00026;author=L+Da+Prato&#x00026;author=M+Ciaccheri&#x00026;author=G+Castelli&#x00026;author=F+Gori&#x00026;author=A+Pizzi+&#x00026;publication_year=2002&#x00026;title=Familial+amyloid+polyneuropathy+with+genetic+anticipation+associated+to+a+gly47glu+transthyretin+variant+in+an+Italian+kindred&#x00026;journal=Amyloid.&#x00026;volume=9&#x00026;pages=35-41\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Long D, Zeng J, Wu LQ, Tang LS, Wang HL, Wang H. Vitreous amyloidosis in two large mainland Chinese kindreds resulting from transthyretin variant Lys35Thr and Leu55Arg. \u003Ci>Ophthalmic Genet.\u003C/i> (2012) 33:28&#x02013;33. doi: 10.3109/13816810.2011.599356\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21843040\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/13816810.2011.599356\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D+Long&#x00026;author=J+Zeng&#x00026;author=LQ+Wu&#x00026;author=LS+Tang&#x00026;author=HL+Wang&#x00026;author=H+Wang+&#x00026;publication_year=2012&#x00026;title=Vitreous+amyloidosis+in+two+large+mainland+Chinese+kindreds+resulting+from+transthyretin+variant+Lys35Thr+and+Leu55Arg&#x00026;journal=Ophthalmic+Genet.&#x00026;volume=33&#x00026;pages=28-33\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Saraiva MJ. Transthyretin mutations in health and disease. \u003Ci>Hum Mutat.\u003C/i> (1995) 5:191&#x02013;6. \u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Saraiva+&#x00026;publication_year=1995&#x00026;title=Transthyretin+mutations+in+health+and+disease&#x00026;journal=Hum+Mutat.&#x00026;volume=5&#x00026;pages=191-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Shiomi K, Nakazato M, Matsukura S, Ohnishi A, Hatanaka H, Tsuji S, et al. A basic transthyretin variant (Glu61&#x02013;&#x0003E;Lys) causes familial amyloidotic polyneuropathy: protein and DNA sequencing and PCR-induced mutation restriction analysis. \u003Ci>Biochem Biophys Res Commun.\u003C/i> (1993) 194:1090&#x02013;6. doi: 10.1006/bbrc.1993.1933\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8352764\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1006/bbrc.1993.1933\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K+Shiomi&#x00026;author=M+Nakazato&#x00026;author=S+Matsukura&#x00026;author=A+Ohnishi&#x00026;author=H+Hatanaka&#x00026;author=S+Tsuji+&#x00026;publication_year=1993&#x00026;title=A+basic+transthyretin+variant+(Glu61&#x02013;&#x0003E;Lys)+causes+familial+amyloidotic+polyneuropathy%3A+protein+and+DNA+sequencing+and+PCR-induced+mutation+restriction+analysis&#x00026;journal=Biochem+Biophys+Res+Commun.&#x00026;volume=194&#x00026;pages=1090-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Holmgren G, Hellman U, Anan I, Lundgren HE, Jonasson J, Stafberg C, et al. Cardiomyopathy in Swedish patients with the Gly53Glu and His88Arg transthyretin variants. \u003Ci>Amyloid.\u003C/i> (2005) 12:184&#x02013;8. doi: 10.1080/13506120500223126\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16194874\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/13506120500223126\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Holmgren&#x00026;author=U+Hellman&#x00026;author=I+Anan&#x00026;author=HE+Lundgren&#x00026;author=J+Jonasson&#x00026;author=C+Stafberg+&#x00026;publication_year=2005&#x00026;title=Cardiomyopathy+in+Swedish+patients+with+the+Gly53Glu+and+His88Arg+transthyretin+variants&#x00026;journal=Amyloid.&#x00026;volume=12&#x00026;pages=184-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. \u003Ci>Amyloid.\u003C/i> (1999) 6:282&#x02013;8. doi: 10.3109/13506129909007341\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10611950\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3109/13506129909007341\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Tachibana&#x00026;author=T+Tokuda&#x00026;author=K+Yoshida&#x00026;author=T+Taketomi&#x00026;author=M+Nakazato&#x00026;author=YF+Li+&#x00026;publication_year=1999&#x00026;title=Usefulness+of+MALDI%2FTOF+mass+spectrometry+of+immunoprecipitated+serum+variant+transthyretin+in+the+diagnosis+of+familial+amyloid+polyneuropathy&#x00026;journal=Amyloid.&#x00026;volume=6&#x00026;pages=282-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Hsu HC, Liao MF, Hsu JL, Lo AL, Kuo HC Lyu RK, et al. Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese. \u003Ci>BMC Neurol.\u003C/i> (2017) 17:178. doi: 10.1186/s12883-017-0957-4\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28882124\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12883-017-0957-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HC+Hsu&#x00026;author=MF+Liao&#x00026;author=JL+Hsu&#x00026;author=AL+Lo&#x00026;author=RK+Kuo+HC+Lyu+&#x00026;publication_year=2017&#x00026;title=Phenotypic+expressions+of+hereditary+Transthyretin+Ala97Ser+related+Amyloidosis+(ATTR)+in+Taiwanese&#x00026;journal=BMC+Neurol.&#x00026;volume=17&#x00026;pages=178\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Low SC, Tan CY, Md Sari NA, Ahmad-Annuar A, Wong KT, Lin KP, et al. Ala97Ser mutation is common among ethnic Chinese Malaysians with transthyretin familial amyloid polyneuropathy. \u003Ci>Amyloid.\u003C/i> (2019) 26:7&#x02013;8. doi: 10.1080/13506129.2019.1582479\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31343308\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/13506129.2019.1582479\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SC+Low&#x00026;author=CY+Tan&#x00026;author=NA+Md+Sari&#x00026;author=A+Ahmad-Annuar&#x00026;author=KT+Wong&#x00026;author=KP+Lin+&#x00026;publication_year=2019&#x00026;title=Ala97Ser+mutation+is+common+among+ethnic+Chinese+Malaysians+with+transthyretin+familial+amyloid+polyneuropathy&#x00026;journal=Amyloid.&#x00026;volume=26&#x00026;pages=7-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Liu YT, Lee YC, Yang CC, Chen ML, Lin KP. Transthyretin Ala97Ser in Chinese-Taiwanese patients with familial amyloid polyneuropathy: genetic studies and phenotype expression. \u003Ci>J Neurol Sci.\u003C/i> (2008) 267:91&#x02013;9. doi: 10.1016/j.jns.2007.10.011\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18022643\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jns.2007.10.011\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=YT+Liu&#x00026;author=YC+Lee&#x00026;author=CC+Yang&#x00026;author=ML+Chen&#x00026;author=KP+Lin+&#x00026;publication_year=2008&#x00026;title=Transthyretin+Ala97Ser+in+Chinese-Taiwanese+patients+with+familial+amyloid+polyneuropathy%3A+genetic+studies+and+phenotype+expression&#x00026;journal=J+Neurol+Sci.&#x00026;volume=267&#x00026;pages=91-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Chao CC, Huang CM, Chiang HH, Luo KR, Kan HW, Yang NC, et al. Sudomotor innervation in transthyretin amyloid neuropathy: Pathology and functional correlates. \u003Ci>Ann Neurol.\u003C/i> (2015) 78:272&#x02013;83. doi: 10.1002/ana.24438\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25973863\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ana.24438\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CC+Chao&#x00026;author=CM+Huang&#x00026;author=HH+Chiang&#x00026;author=KR+Luo&#x00026;author=HW+Kan&#x00026;author=NC+Yang+&#x00026;publication_year=2015&#x00026;title=Sudomotor+innervation+in+transthyretin+amyloid+neuropathy%3A+Pathology+and+functional+correlates&#x00026;journal=Ann+Neurol.&#x00026;volume=78&#x00026;pages=272-83\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Castiglione V, Franzini M, Aimo A, Carecci A, Lombardi CM, Passino C, et al. Use of biomarkers to diagnose and manage cardiac amyloidosis. \u003Ci>Eur J Heart Fail.\u003C/i> (2021) 23:217&#x02013;30. doi: 10.1002/ejhf.2113\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33527656\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ejhf.2113\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V+Castiglione&#x00026;author=M+Franzini&#x00026;author=A+Aimo&#x00026;author=A+Carecci&#x00026;author=CM+Lombardi&#x00026;author=C+Passino+&#x00026;publication_year=2021&#x00026;title=Use+of+biomarkers+to+diagnose+and+manage+cardiac+amyloidosis&#x00026;journal=Eur+J+Heart+Fail.&#x00026;volume=23&#x00026;pages=217-30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. a position statement of the European Society of cardiology working group on myocardial and pericardial diseases. \u003Ci>Eur J Heart Fail.\u003C/i> (2021) 23:512&#x02013;26. doi: 10.1002/ejhf.2140\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33826207\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ejhf.2140\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P+Garcia-Pavia&#x00026;author=C+Rapezzi&#x00026;author=Y+Adler&#x00026;author=M+Arad&#x00026;author=C+Basso&#x00026;author=A+Brucato+&#x00026;publication_year=2021&#x00026;title=Diagnosis+and+treatment+of+cardiac+amyloidosis.+a+position+statement+of+the+European+Society+of+cardiology+working+group+on+myocardial+and+pericardial+diseases&#x00026;journal=Eur+J+Heart+Fail.&#x00026;volume=23&#x00026;pages=512-26\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Suhr OB, Herlenius G, Friman S, Ericzon BG. Liver transplantation for hereditary transthyretin amyloidosis. \u003Ci>Liver Transpl.\u003C/i> (2000) 6:263&#x02013;76. doi: 10.1053/lv.2000.6145\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10827225\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1053/lv.2000.6145\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=OB+Suhr&#x00026;author=G+Herlenius&#x00026;author=S+Friman&#x00026;author=BG+Ericzon+&#x00026;publication_year=2000&#x00026;title=Liver+transplantation+for+hereditary+transthyretin+amyloidosis&#x00026;journal=Liver+Transpl.&#x00026;volume=6&#x00026;pages=263-76\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. \u003Ci>Liver Transpl.\u003C/i> (2015) 21:282&#x02013;92. doi: 10.1002/lt.24058\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25891323\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/lt.24058\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Carvalho&#x00026;author=A+Rocha&#x00026;author=L+Lobato+&#x00026;publication_year=2015&#x00026;title=Liver+transplantation+in+transthyretin+amyloidosis%3A+issues+and+challenges&#x00026;journal=Liver+Transpl.&#x00026;volume=21&#x00026;pages=282-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. \u003Ci>Neurology.\u003C/i> (2010) 75:324&#x02013;7. doi: 10.1212/WNL.0b013e3181ea15d4\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20660862\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1212/WNL.0b013e3181ea15d4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JJ+Liepnieks&#x00026;author=LQ+Zhang&#x00026;author=MD+Benson+&#x00026;publication_year=2010&#x00026;title=Progression+of+transthyretin+amyloid+neuropathy+after+liver+transplantation&#x00026;journal=Neurology.&#x00026;volume=75&#x00026;pages=324-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\n\u003Cdiv class=\"AbstractSummary\">\n\u003Cp>\u003Cspan>Keywords:\u003C/span> hereditary, transthyretin amyloidosis, cardiomyopathy, prognosis, China\u003C/p>\n\u003Cp>\u003Cspan>Citation:\u003C/span> Wang S, Peng W, Pang M, Mao L, Peng D, Yu B, Wu S, Hu D, Yang Y, He J and Ouyang M (2022) Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China. \u003Ci>Front. Cardiovasc. Med.\u003C/i> 9:900313. doi: 10.3389/fcvm.2022.900313\u003C/p>\n\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 20 March 2022; \u003Cspan>Accepted:\u003C/span> 07 June 2022;\u003Cbr> \u003Cspan>Published:\u003C/span> 27 June 2022.\u003C/p>\n\u003Cdiv>\u003Cp>Edited by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/1401135/overview\">Jeffrey Shi Kai Chan\u003C/a>, Cardiovascular Analytics Group, Hong Kong SAR, China\u003C/div>\n\u003Cdiv>\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/788222/overview\">Concetta Zito\u003C/a>, University of Messina, Italy\u003Cbr> \u003Ca href=\"http://loop.frontiersin.org/people/820312/overview\">Marcus V. Pinto\u003C/a>, Mayo Clinic, United States\u003C/div>\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2022 Wang, Peng, Pang, Mao, Peng, Yu, Wu, Hu, Yang, He and Ouyang. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\n\u003Cp>\u003Cspan>&#x0002A;Correspondence:\u003C/span> Daoquan Peng, \u003Ca id=\"encmail\">cGVuZ2RxQGNzdS5lZHUuY24=\u003C/a>\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h3\">Methods\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h7\">Data Availability Statement\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h8\">Ethics Statement\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h10\">Funding\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h11\">Conflict of Interest\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h12\">Publisher&#x00027;s Note\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h13\">Acknowledgments\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h14\">Supplementary Material\u003C/a>\u003C/li>\n\u003Cli>\u003Ca href=\"#h15\">References\u003C/a>\u003C/li>\n\u003C/ul>",[676,681,687,690,696],{"name":677,"fileServerPackageEntryId":19,"fileServerId":678,"fileServerVersionNumber":390,"type":679},"EPUB.epub","900313/epub",{"code":680,"name":680},"EPUB",{"name":682,"fileServerPackageEntryId":683,"fileServerId":684,"fileServerVersionNumber":390,"type":685},"fcvm-09-900313.pdf","fcvm-09-900313/fcvm-09-900313.pdf","900313/pubmed-zip",{"code":686,"name":686},"PDF",{"name":682,"fileServerPackageEntryId":19,"fileServerId":688,"fileServerVersionNumber":390,"type":689},"900313/publishers-proof/pdf",{"code":686,"name":686},{"name":691,"fileServerPackageEntryId":692,"fileServerId":684,"fileServerVersionNumber":390,"type":693},"fcvm-09-900313.xml","fcvm-09-900313/fcvm-09-900313.xml",{"code":694,"name":695},"NLM_XML","XML",{"name":697,"fileServerPackageEntryId":19,"fileServerId":698,"fileServerVersionNumber":390,"type":699},"Provisional PDF.pdf","900313/provisional-pdf",{"code":686,"name":686},"v3",{"title":702,"link":703,"meta":707,"script":840},"Frontiers | Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China",[704],{"rel":705,"href":706},"canonical","https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/full",[708,711,714,716,719,723,726,730,733,736,739,741,743,745,747,749,752,755,757,760,762,764,767,770,773,776,779,783,787,790,792,795,797,800,802,805,807,810,812,815,817,820,822,825,827,830,832,835,837],{"hid":709,"property":709,"name":709,"content":710},"description","Background: Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is a genotypically heterogeneous disorder with a poor prognosis. There is limited liter...",{"hid":712,"property":712,"name":713,"content":702},"og:title","title",{"hid":715,"property":715,"name":709,"content":710},"og:description",{"hid":717,"name":717,"content":718},"keywords","hereditary,transthyretin amyloidosis,cardiomyopathy,prognosis,China",{"hid":720,"property":720,"name":721,"content":722},"og:site_name","site_name","Frontiers",{"hid":724,"property":724,"name":383,"content":725},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/900313/fcvm-09-900313-HTML/image_m/fcvm-09-900313-g001.jpg",{"hid":727,"property":727,"name":728,"content":729},"og:type","type","article",{"hid":731,"property":731,"name":732,"content":706},"og:url","url",{"hid":734,"name":734,"content":735},"twitter:card","summary_large_image",{"hid":737,"name":737,"content":738},"citation_volume","9",{"hid":740,"name":740,"content":116},"citation_journal_title",{"hid":742,"name":742,"content":722},"citation_publisher",{"hid":744,"name":744,"content":656},"citation_journal_abbrev",{"hid":746,"name":746,"content":657},"citation_issn",{"hid":748,"name":748,"content":533},"citation_doi",{"hid":750,"name":750,"content":751},"citation_firstpage","900313",{"hid":753,"name":753,"content":754},"citation_language","English",{"hid":756,"name":756,"content":534},"citation_title",{"hid":758,"name":758,"content":759},"citation_keywords","hereditary; transthyretin amyloidosis; cardiomyopathy; prognosis; China",{"hid":761,"name":761,"content":539},"citation_abstract",{"hid":763,"name":763,"content":548},"citation_article_type",{"hid":765,"name":765,"content":766},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/pdf",{"hid":768,"name":768,"content":769},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.900313/xml",{"hid":771,"name":771,"content":772},"citation_fulltext_world_readable","yes",{"hid":774,"name":774,"content":775},"citation_online_date","2022/06/07",{"hid":777,"name":777,"content":778},"citation_publication_date","2022/06/27",{"hid":780,"name":781,"content":782},"citation_author_0","citation_author","Wang, Shuai ",{"hid":784,"name":785,"content":786},"citation_author_institution_0","citation_author_institution","Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, China",{"hid":788,"name":781,"content":789},"citation_author_1","Peng, Wenke ",{"hid":791,"name":785,"content":786},"citation_author_institution_1",{"hid":793,"name":781,"content":794},"citation_author_2","Pang, Min ",{"hid":796,"name":785,"content":786},"citation_author_institution_2",{"hid":798,"name":781,"content":799},"citation_author_3","Mao, Ling ",{"hid":801,"name":785,"content":786},"citation_author_institution_3",{"hid":803,"name":781,"content":804},"citation_author_4","Peng, Daoquan ",{"hid":806,"name":785,"content":786},"citation_author_institution_4",{"hid":808,"name":781,"content":809},"citation_author_5","Yu, Bilian ",{"hid":811,"name":785,"content":786},"citation_author_institution_5",{"hid":813,"name":781,"content":814},"citation_author_6","Wu, Sha ",{"hid":816,"name":785,"content":786},"citation_author_institution_6",{"hid":818,"name":781,"content":819},"citation_author_7","Hu, Die ",{"hid":821,"name":785,"content":786},"citation_author_institution_7",{"hid":823,"name":781,"content":824},"citation_author_8","Yang, Yang ",{"hid":826,"name":785,"content":786},"citation_author_institution_8",{"hid":828,"name":781,"content":829},"citation_author_9","He, Jia ",{"hid":831,"name":785,"content":786},"citation_author_institution_9",{"hid":833,"name":781,"content":834},"citation_author_10","Ouyang, Mingqi ",{"hid":836,"name":785,"content":786},"citation_author_institution_10",{"hid":838,"name":838,"content":839},"dc.identifier","doi:10.3389/fcvm.2022.900313",[841,844,846,848,850],{"src":842,"body":13,"type":843,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":845,"body":13,"type":843,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":847,"body":13,"type":843,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":849,"body":13,"type":843,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fcvm.2022.900313?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":851,"body":13,"type":843,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":853,"articleHubArticlesList":854,"canJournalHasArticleHub":375,"articleDoiList":855},{},[],[],{"title":19,"image":-1,"breadcrumbs":857,"linksCollection":858,"metricsCollection":860},[],{"total":387,"items":859},[],{"total":387,"items":861},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fcvm.2022.900313?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>